

PUBLICATIONS CLB - CRCL 2015

1. Al Akoum C, Akl I, Rouas R, Fayyad-Kazan M, Falha L, Renno T, Burny A, Lewalle P, Fayyad-Kazan H, Badran B: NFAT-1, Sp-1, Sp-3, and miR-21: New regulators of chemokine C receptor 7 expression in mature human dendritic cells. *Hum Immunol* 76:307-317, 2015
2. Alchab F, Ettouati L, Bouaziz Z, Bollacke A, Delcros JG, Gertzen CG, Gohlke H, Pinaud N, Marchivie M, Guillon J, Fenet B, Jose J, Borgne ML: Synthesis, Biological Evaluation and Molecular Modeling of Substituted Indeno[1,2-b]indoles as Inhibitors of Human Protein Kinase CK2. *Pharmaceuticals (Basel)* 8:279-302, 2015
3. Alioto TS, Buchhalter I, Derdak S, Hutter B, Eldridge MD, Hovig E, Heisler LE, Beck TA, Simpson JT, Tonon L, Sertier AS, Patch AM, Jager N, Ginsbach P, Drews R, Paramasivam N, Kabbe R, Chotewutmontri S, Diessl N, Previti C, Schmidt S, Brors B, Feuerbach L, Heinold M, Grobner S, Korshunov A, Tarpey PS, Butler AP, Hinton J, Jones D, Menzies A, Raine K, Shepherd R, Stebbings L, Teague JW, Ribeca P, Giner FC, Beltran S, Raineri E, Dabad M, Heath SC, Gut M, Denroche RE, Harding NJ, Yamaguchi TN, Fujimoto A, Nakagawa H, Quesada V, Valdes-Mas R, Nakken S, Vodak D, Bower L, Lynch AG, Anderson CL, Waddell N, Pearson JV, Grimmond SM, Peto M, Spellman P, He M, Kandoth C, Lee S, Zhang J, Letourneau L, Ma S, Seth S, Torrents D, Xi L, Wheeler DA, Lopez-Otin C, Campo E, Campbell PJ, Boutros PC, Puente XS, Gerhard DS, Pfister SM, McPherson JD, Hudson TJ, Schlesner M, Lichter P, Eils R, Jones DT, Gut IG: A comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing. *Nat Commun* 6:10001, 2015
4. Amet S, Bronowicki JP, Thabut D, Zoulim F, Bourliere M, Mathurin P, de Ledinghen V, Benhamou Y, Larrey DG, Janus N, Deray G, Launay-Vacher V, Pol S. Prevalence of renal abnormalities in chronic HBV infection: the HARPE study. *Liver Int.* 2015 Jan;35(1):148-55.
5. Amin SM, Cooper C, Yelamos O, Lee CY, Sholl LM, De La Fouchardiere A, Guitart J, Gerami P: Combined cutaneous tumors with a melanoma component: A clinical, histologic, and molecular study. *J Am Acad Dermatol* 73:451-460, 2015
6. Ansieau S, Collin G: Senescence versus apoptosis in chemotherapy. *Oncotarget* 6:4551-4552, 2015
7. Aouacheria A, Combet C, Tompa P, Hardwick JM: Redefining the BH3 Death Domain as a 'Short Linear Motif'. *Trends Biochem Sci* 40:736-748, 2015

8. Apetoh L, Smyth MJ, Drake CG, Abastado JP, Apte RN, Ayyoub M, Blay JY, Bonneville M, Butterfield LH, Caignard A, Castelli C, Cavallo F, Celis E, Chen L, Colombo MP, Comin-Anduix B, Coukos G, Dhodapkar MV, Dranoff G, Frazer IH, Fridman WH, Gibrilovich DI, Gilboa E, Gnjatic S, Jager D, Kalinski P, Kaufman HL, Kiessling R, Kirkwood J, Knuth A, Liblau R, Lotze MT, Lugli E, Marincola F, Melero I, Melief CJ, Mempel TR, Mittendorf EA, Odun K, Overwijk WW, Palucka AK, Parmiani G, Ribas A, Romero P, Schreiber RD, Schuler G, Srivastava PK, Tartour E, Valmori D, van der Burg SH, van der Bruggen P, van den Eynde BJ, Wang E, Zou W, Whiteside TL, Speiser DE, Pardoll DM, Restifo NP, Anderson AC: Consensus nomenclature for CD8 T cell phenotypes in cancer. *Oncoimmunology* 4:e998538, 2015
9. Arbiol E, Brasy S, Morliere L: [Care-related pain in patients with cancer]. *Rev Infirm* 210:19-20, 2015
10. Arbor N, Dauvergne D, Dedes G, Letang JM, Parodi K, Quinones CT, Testa E, Rit S: Monte Carlo comparison of x-ray and proton CT for range calculations of proton therapy beams. *Phys Med Biol* 60:7585-7599, 2015
11. Arthur C, Cermak J, Delaunay J, Mayer J, Mazur G, Thomas X, Wierzbowska A, Jones MM, Berrak E, Kantarjian H. Post hoc analysis of the relationship between baseline white blood cell count and survival outcome in a randomized Phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia. *J Blood Med*, 2015; 6(25-29).
12. Avril MF, Bahadoran P, Cabaret O, Caron O, De La Fouchardiere A, Demenais F, Desjardins L, Frebourg T, Hammel P, Leccia MT, Lesueur F, Mahe E, Martin L, Maubec E, Remenieras A, Richard S, Robert C, Soufir N, Stoppa-Lyonnet D, Thomas L, Vabres P, Bressac-de PB: [Recommendations for genetic testing and management of individuals genetically at-risk of cutaneous melanoma]. *Ann Dermatol Venereol* 142:26-36, 2015
13. Avrillon V, Locatelli-Sanchez M, Folliet L, Carbonnaux M, Perino E, Fossard G, Desseigne M, Freymond N, Geriniere L, Perrot E, Souquet PJ, Couraud S: Lung cancer may increase serum procalcitonin level. *Infect Disord Drug Targets* 15:57-63, 2015
14. Baas P, Fennell D, Kerr KM, Van Schil PE, Haas RL, Peters S; ESMO Guidelines Committee. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2015 Sep;26 Suppl 5:v31-9.
15. Bachelet JT, Combemale P, Devic C, Foray N, Jouanneau E, Breton P: [Management of craniofacial type 1 neurofibromatosis]. *Rev Stomatol Chir Maxillofac Chir Orale* 116:209-214, 2015
16. Bailly F, Hartig-Lavie K, Lebossé F, Pagès-Ecochard M, Zoulim F. [Viral hepatitis]. *Rev Prat*. 2015 Feb;65(2):259-68.

17. Bailly F, Hartig-Lavie K, Lebossé F, Pagès-Ecochard M, Zoulim F. [Treatment of hepatitis C: decisive therapeutic advances]. *Rev Prat.* 2015 Feb;65(2):255-6.
18. Bailly F, Virlogeux V, Dufour C, Pradat P, Hézode C, Larrey D, Alric L, Samuel, D, Bourlière M, Métivier S, Zarski JP, Fontaine H, Loustaud-Ratti V, Serfaty L, Bronowicki JP, Carrat F, Zoulim F; CUPIC Study Group. Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen - The ANRS CO20-CUPIC study. *Clin Res Hepatol Gastroenterol.* 2015 Jan 27. pii: S2210-7401(15)00002-9
19. Baldacci F, Mittone A, Bravin A, Coan P, Delaire F, Ferrero C, Gasilov S, Letang JM, Sarrut D, Smekens F, Freud N: A track length estimator method for dose calculations in low-energy X-ray irradiations: implementation, properties and performance. *Z Med Phys* 25:36-47, 2015
20. Baldeck N, Janel-Bintz R, Wagner J, Tissier A, Fuchs RP, Burkovics P, Haracska L, Despras E, Bichara M, Chatton B, Cordonnier AM. FF483-484 motif of human Pol η mediates its interaction with the POLD2 subunit of Pol δ and contributes to DNA damage tolerance. *Nucleic Acids Res.* 2015 Feb 27;43(4):2116-25
21. Bally O, Tassy L, Richioud B, Decouvelaere AV, Blay JY, Derbel O: Eight years tumor control with pazopanib for a metastatic resistant epithelioid hemangi endothelioma. *Clin Sarcoma Res* 5:12, 2015
22. Barba T, Maucort-Boulch D, Iwaz J, Bohe J, Ninet J, Hot A, Lega JC, Guerin C, Argaud L, Broussolle C, Jamilloux Y, Richard JC, Seve P. Hemophagocytic Lymphohistiocytosis in Intensive Care Unit: A 71-Case Strobe-Compliant Retrospective Study. *Medicine (Baltimore)*, 2015; 94(51): e2318.
23. Barrios CH, Blackstein ME, Blay JY, Casali PG, Chacon M, Gu J, Kang YK, Nishida T, Purkayastha D, Woodman RC, Reichardt P. The GOLD ReGISTry: a Global, Prospective, Observational Registry Collecting Longitudinal Data on Patients with Advanced and Localised Gastrointestinal Stromal Tumours. *Eur J Cancer.* 2015 Nov;51(16):2423-33
24. Bartosch B. Piecing together the key players of fibrosis in chronic hepatitis C: what roles do non-hepatic liver resident cell types play? *Gut.* 2015 Jun;64(6):862-3.
25. Beji H, de la Fouchardiere C, Desseigne F, Thiesse P, Richioud B, Pilleul F: Thrombocytopenia due to hypersplenism in oncological disease: partial splenic embolization during palliative treatment. *Diagn Interv Imaging* 96:383-386, 2015
26. Beji H, Thiesse P: "Pelvic ribs": A rare congenital abnormality. *Diagn Interv Imaging* 96:525-527, 2015

27. Beji H, Thiesse P: Asymptomatic and incidentally discovered calcification of the gluteal region. *Diagn Interv Imaging* 96:523-524, 2015
28. Beji H, Zrounba P, Blay JY, Richioud B, Pilleul F: Hemorrhage due to radiation-induced sarcoma of the mandible: treatment with percutaneous cryotherapy. *Diagn Interv Imaging* 96:407-409, 2015
29. Bellera CA, Penel N, Ouali M, Bonvalot S, Casali PG, Nielsen OS, Delannes M, Litiere S, Bonnetain F, Dabakuyo TS, Benjamin RS, Blay JY, Bui BN, Collin F, Delaney TF, Duffaud F, Filleron T, Fiore M, Gelderblom H, George S, Grimer R, Grosclaude P, Gronchi A, Haas R, Hohenberger P, Issels R, Italiano A, Jooste V, Krarup-Hansen A, Le PC, Mussi C, Oberlin O, Patel S, Piperno-Neumann S, Raut C, Ray-Coquard I, Rutkowski P, Schuetze S, Sleijfer S, Stoeckle E, Van GM, Woll P, Gourgou-Bourgade S, Mathoulin-Pelissier S: Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)dagger. *Ann Oncol* 26:865-872, 2015
30. Bellini A, Bernard V, Leroy Q, Rio FT, Pierron G, Combaret V, Lapouble E, Clement N, Rubie H, Thebaud E, Chastagner P, Defachelles AS, Bergeron C, Buchbinder N, Taque S, Auvrignon A, Valteau-Couanet D, Michon J, Janoueix-Lerosey I, Delattre O, Schleiermacher G: Deep Sequencing Reveals Occurrence of Subclonal ALK Mutations in Neuroblastoma at Diagnosis. *Clin Cancer Res* 21:4913-4921, 2015
31. Ben Arush M, Minard-Colin V, Mosseri V, Defachelles AS, Bergeron C, Algret N, Fasola S, Andre N, Thebaud E, Corradini N, Bernier V, Martelli H, Ranchere D, Orbach D: Does aggressive local treatment have an impact on survival in children with metastatic rhabdomyosarcoma? *Eur J Cancer* 51:193-201, 2015
32. Benusiglio PR, Colas C, Rouleau E, Uhrhammer N, Romero P, Remenieras A, Moretta J, Wang Q, de PA, Buecher B, Stoppa-Lyonnet D, Mouret-Fourme E, Nogues C, Di MM, Tlemsani C, Warcoin M, Grandjouan S, Malka D, Caron O, Blayau M: Hereditary diffuse gastric cancer syndrome: improved performances of the 2015 testing criteria for the identification of probands with a CDH1 germline mutation. *J Med Genet* 52:563-565, 2015
33. Bergeron C, Coze C, Segura C, Pacquement H, Gandemer V, Ducassou S, Patte C: Treatment of Childhood T-Cell Lymphoblastic Lymphoma-Long-Term Results of the SFOP LMT96 Trial. *Pediatr Blood Cancer* 62:2150-2156, 2015
34. Bernadou G, Campone M, Merlin JL, Gouilleux-Gruart V, Bachelot T, Lokiec F, Rezai K, Arnedos M, Dieras V, Jimenez M, Paintaud G, Ternant D: Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancer. *Br J Clin Pharmacol* 2015

35. Bernard C, Bailly F, Craigherot F, Bancel B, Brevet M, Broussolle C, Seve P, Belenotti P. Asthenia, weight loss and abdominal pain in a 64-year-old woman. *Rev Med Interne*, 2015; 36(10): 706-709.
36. Bernard D, Wiel C: Transport and senescence. *Oncoscience* 2:741-742, 2015
37. Bertolotto C, Lesueur F, Giuliano S, Strub T, de Lichy M, Bille K, Dessen P, d'Hayer B, Mohamdi H, Remenieras A, Maubec E, de la Fouchardière A, Molinié V, Vabres P, Dalle S, Poulalhon N, Martin-Denavit T, Thomas L, Andry-Benzaquen P, Dupin N, Boitier F, Rossi A, Perrot JL, Labeille B, Robert C, Escudier B, Caron O, Brugières L, Saule S, Gardie B, Gad S, Richard S, Couturier J, Teh BT, Ghiorzo P, Pastorino L, Puig S, Badenas C, Olsson H, Ingvar C, Rouleau E, Lidereau R, Bahadoran P, Vielh P, Corda E, Blanché H, Zelenika D, Galan P; French Familial Melanoma Study Group, Chaudru V, Lenoir GM, Lathrop M, Davidson I, Avril MF, Demenais F, Ballotti R, Bressac-de Paillerets B. Corrigendum: A SUMOylation-defective MITF germline mutation predisposes to melanoma and renal carcinoma. *Nature*. 2015 Dec 2.
38. Besse B, Le MS, Mazieres J, Senellart H, Barlesi F, Chouaid C, Dansin E, Berard H, Falchero L, Gervais R, Robinet G, Ruppert AM, Schott R, Lena H, Clement-Duchene C, Quantin X, Souquet PJ, Tredaniel J, Moro-Sibilot D, Perol M, Madroszyk AC, Soria JC: Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study. *Clin Cancer Res* 21:1896-1903, 2015
39. Bielefeld P, Devilliers H, Deschasse C, Saadoun D, Seve P, Muselier A, Creuzot-Garcher C, Besancenot JF, Bron AM. Potential of Pegylated Interferon Alpha-2a in Behcet Uveitis: A Report of Five Cases. *Ocul Immunol Inflamm*, 2015; 1-4.
40. Bigeard C: [Caring for patients with cancer wounds]. *Rev Infirm* 210:45-46, 2015
41. Blanco I, Kuchenbaecker K, Cuadras D, Wang X, Barrowdale D, de Garibay GR, Librado P, Sanchez-Gracia A, Rozas J, Bonifaci N, McGuffog L, Pankratz VS, Islam A, Mateo F, Berenguer A, Petit A, Catala I, Brunet J, Feliubadalo L, Tornero E, Benitez J, Osorio A, Cajal T, Nevanlinna H, Aittomaki K, Arun BK, Toland AE, Karlan BY, Walsh C, Lester J, Greene MH, Mai PL, Nussbaum RL, Andrulis IL, Domchek SM, Nathanson KL, Rebbeck TR, Barkardottir RB, Jakubowska A, Lubinski J, Durda K, Jaworska-Bieniek K, Claes K, Van MT, Diez O, Hansen TV, Jonson L, Gerdes AM, Ejlertsen B, de la Hoya M, Caldes T, Dunning AM, Oliver C, Fineberg E, Cook M, Peock S, McCann E, Murray A, Jacobs C, Pichert G, Lalloo F, Chu C, Dorkins H, Paterson J, Ong KR, Teixeira MR, Hogervorst FB, van der Hout AH, Seynaeve C, van der Luijt RB, Ligtenberg MJ, Devilee P, Wijnen JT, Rookus MA, Meijers-Heijboer HE, Blok MJ, van den Ouweland AM, Aalfs CM, Rodriguez GC, Phillips KA, Piedmonte M, Nerenstone SR, Bae-Jump VL, O'Malley DM, Ratner ES, Schmutzler RK, Wappenschmidt B, Rhiem K, Engel C, Meindl A, Ditsch N, Arnold N, Plendl HJ, Niederacher D,

- Sutter C, Wang-Gohrke S, Steinemann D, Preisler-Adams S, Kast K, Varon-Mateeva R, Gehrig A, Bojesen A, Pedersen IS, Sunde L, Jensen UB, Thomassen M, Kruse TA, Foretova L, Peterlongo P, Bernard L, Peissel B, Scuvera G, Manoukian S, Radice P, Ottini L, Montagna M, Agata S, Maugard C, Simard J, Soucy P, Berger A, Fink-Retter A, Singer CF, Rappaport C, Geschwantler-Kaulich D, Tea MK, Pfeiler G, John EM, Miron A, Neuhausen SL, Terry MB, Chung WK, Daly MB, Goldgar DE, Janavicius R, Dorfling CM, van Rensburg EJ, Fostira F, Konstantopoulou I, Garber J, Godwin AK, Olah E, Narod SA, Rennert G, Paluch SS, Laitman Y, Friedman E, Liljegren A, Rantala J, Stenmark-Askmal M, Loman N, Imyanitov EN, Hamann U, Spurdle AB, Healey S, Weitzel JN, Herzog J, Margileth D, Gorrini C, Esteller M, Gomez A, Sayols S, Vidal E, Heyn H, Stoppa-Lyonnet D, Leone M, Barjhoux L, Fassy-Colcombet M, de PA, Lasset C, Ferrer SF, Castera L, Berthet P, Cornelis F, Bignon YJ, Damiola F, Mazoyer S, Sinilnikova OM, Maxwell CA, Vijai J, Robson M, Kauff N, Corines MJ, Villano D, Cunningham J, Lee A, Lindor N, Lazaro C, Easton DF, Offit K, Chenevix-Trench G, Couch FJ, Antoniou AC, Pujana MA: Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers. *PLoS One* 10:e0120020, 2015
42. Blay JY, Casali PG, Dei Tos AP, Le CA, Reichardt P: Management of Gastrointestinal Stromal Tumour: Current Practices and Visions for the Future. *Oncology* 89:1-13, 2015
43. Blay JY, Hurh E, Green S, Novick S: Nilotinib versus imatinib for G. *Lancet Oncol* 16:e311-e312, 2015
44. Blay JY, Papai Z, Tolcher AW, Italiano A, Cupissol D, Lopez-Pousa A, Chawla SP, Bompas E, Babovic N, Penel N, Isambert N, Staddon AP, Saada-Bouزيد E, Santoro A, Franke FA, Cohen P, Le-Guenec S, Demetri GD: Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol* 16:531-540, 2015
45. Blay JY, Shen L, Kang YK, Rutkowski P, Qin S, Nosov D, Wan D, Trent J, Srimuninnimit V, Papai Z, Le CA, Novick S, Tanningco L, Mo S, Green S, Reichardt P, Demetri GD: Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial. *Lancet Oncol* 16:550-560, 2015
46. Blay JY, Tredan O, Ray-Coquard I, Rivoire M, Mehlen P, Puisieux A, Bachelot T: [Quinze questions importantes a se poser en oncologie en 2015]. *Bull Cancer* 102:S22-S26, 2015
47. Blein S, Bardel C, Danjean V, McGuffog L, Healey S, Barrowdale D, Lee A, Dennis J, Kuchenbaecker KB, Soucy P, Terry MB, Chung WK, Goldgar DE, Buys SS, Janavicius R, Tihomirova L, Tung N, Dorfling CM, van Rensburg EJ,

- Neuhausen SL, Ding YC, Gerdes AM, Ejlersen B, Nielsen FC, Hansen TV, Osorio A, Benitez J, Conejero RA, Segota E, Weitzel JN, Thelander M, Peterlongo P, Radice P, Pensotti V, Dolcetti R, Bonanni B, Peissel B, Zaffaroni D, Scuvera G, Manoukian S, Varesco L, Capone GL, Papi L, Ottini L, Yannoukakos D, Konstantopoulou I, Garber J, Hamann U, Donaldson A, Brady A, Brewer C, Foo C, Evans DG, Frost D, Eccles D, Douglas F, Cook J, Adlard J, Barwell J, Walker L, Izatt L, Side LE, Kennedy MJ, Tischkowitz M, Rogers MT, Porteous ME, Morrison PJ, Platte R, Eeles R, Davidson R, Hodgson S, Cole T, Godwin AK, Isaacs C, Claes K, De LK, Meindl A, Gehrig A, Wappenschmidt B, Sutter C, Engel C, Niederacher D, Steinemann D, Plendl H, Kast K, Rhiem K, Ditsch N, Arnold N, Varon-Mateeva R, Schmutzler RK, Preisler-Adams S, Markov NB, Wang-Gohrke S, de PA, Lefol C, Lasset C, Leroux D, Rouleau E, Damiola F, Dreyfus H, Barjhoux L, Golmard L, Uhrhammer N, Bonadona V, Sornin V, Bignon YJ, Carter J, Van LL, Piedmonte M, DiSilvestro PA, de la Hoya M, Caldes T, Nevanlinna H, Aittomaki K, Jager A, van den Ouweland AM, Kets CM, Aalfs CM, van Leeuwen FE, Hogervorst FB, Meijers-Heijboer HE, Oosterwijk JC, van Roozendaal KE, Rookus MA, Devilee P, van der Luijt RB, Olah E, Diez O, Teule A, Lazaro C, Blanco I, Del VJ, Jakubowska A, Sukiennicki G, Gronwald J, Lubinski J, Durda K, Jaworska-Bieniek K, Agnarsson BA, Maugard C, Amadori A, Montagna M, Teixeira MR, Spurdle AB, Foulkes W, Olswold C, Lindor NM, Pankratz VS, Szabo CI, Lincoln A, Jacobs L, Corines M, Robson M, Vijai J, Berger A, Fink-Retter A, Singer CF, Rappaport C, Kaulich DG, Pfeiler G, Tea MK, Greene MH, Mai PL, Rennert G, Imyanitov EN, Mulligan AM, Glendon G, Andrulis IL, Tchatchou S, Toland AE, Pedersen IS, Thomassen M, Kruse TA, Jensen UB, Caligo MA, Friedman E, Zidan J, Laitman Y, Lindblom A, Melin B, Arver B, Loman N, Rosenquist R, Olopade OI, Nussbaum RL, Ramus SJ, Nathanson KL, Domchek SM, Rebbeck TR, Arun BK, Mitchell G, Karlan BY, Lester J, Orsulic S, Stoppa-Lyonnet D, Thomas G, Simard J, Couch FJ, Offit K, Easton DF, Chenevix-Trench G, Antoniou AC, Mazoyer S, Phelan CM, Sinilnikova OM, Cox DG: An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. *Breast Cancer Res* 17:61, 2015
48. Blein S, Barjhoux L, Damiola F, Dondon MG, Eon-Marchais S, Marcou M, Caron O, Lortholary A, Buecher B, Vennin P, Berthet P, Nogues C, Lasset C, Gauthier-Villars M, Mazoyer S, Stoppa-Lyonnet D, Andrieu N, Thomas G, Sinilnikova OM, Cox DG: Targeted Sequencing of the Mitochondrial Genome of Women at High Risk of Breast Cancer without Detectable Mutations in BRCA1/2. *PLoS One* 10:e0136192, 2015
49. Bodard AG, Salino S, Desoutter A, Deneuve S: Assessment of functional improvement with implant-supported prosthetic rehabilitation after mandibular reconstruction with a microvascular free fibula flap: A study of 25 patients. *J Prosthet Dent* 113:140-145, 2015
50. Bodo S, Colas C, Buhard O, Collura A, Tinat J, Lavoine N, Guilloux A, Chalastanis A, Lafitte P, Coulet F, Buisine MP, Ilencikova D, Ruiz-Ponte C,

- Kinzel M, Grandjouan S, Brems H, Lejeune S, Blanche H, Wang Q, Caron O, Cabaret O, Svrcek M, Vidaud D, Parfait B, Verloes A, Knappe UJ, Soubrier F, Mortemousque I, Leis A, Auclair-Perrossier J, Frebourg T, Flejou JF, Entz-Werle N, Leclerc J, Malka D, Cohen-Haguenuer O, Goldberg Y, Gerdes AM, Fedhila F, Mathieu-Dramard M, Hamelin R, Wafaa B, Gauthier-Villars M, Bourdeaut F, Sheridan E, Vasen H, Brugieres L, Wimmer K, Muleris M, Duval A: Diagnosis of Constitutional Mismatch Repair-Deficiency Syndrome Based on Microsatellite Instability and Lymphocyte Tolerance to Methylating Agents. *Gastroenterology* 149:1017-1029, 2015
51. Boespflug A, Guerra J, Dalle S, Thomas L. Enhancement of Customary Dermoscopy Education With Spaced Education e-Learning: A Prospective Controlled Trial. *JAMA Dermatol.* 2015 Aug;151(8):847-53
 52. Bogaerts J, Sydes MR, Keat N, McConnell A, Benson A, Ho A, Roth A, Fortpied C, Eng C, Peckitt C, Coens C, Pettaway C, Arnold D, Hall E, Marshall E, Sclafani F, Hatcher H, Earl H, Ray-Coquard I, Paul J, Blay JY, Whelan J, Panageas K, Wheatley K, Harrington K, Licitra L, Billingham L, Hensley M, McCabe M, Patel PM, Carvajal R, Wilson R, Glynne-Jones R, McWilliams R, Leyvraz S, Rao S, Nicholson S, Filiaci V, Negrouk A, Lacombe D, Dupont E, Pauporte I, Welch JJ, Law K, Trimble T, Seymour M: Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative. *Eur J Cancer* 51:271-281, 2015
 53. Bompas E, Le CA, Tresch-Bruneel E, Lebellec L, Laurence V, Collard O, Saada-Bouid E, Isambert N, Blay JY, Amela EY, Salas S, Chevreau C, Bertucci F, Italiano A, Clisant S, Penel N: Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO). *Ann Oncol* 26:2168-2173, 2015
 54. Bonnefoi H, Jacot W, Saghatchian M, Moldovan C, Venat-Bouvet L, Zaman K, Matos E, Petit T, Bodmer A, Quenel-Tueux N, Chakiba C, Vuylsteke P, Jerusalem G, Brain E, Tredan O, Messina CG, Slaets L, Cameron D: Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study. *Ann Oncol* 26:325-332, 2015
 55. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhaufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crino L, Blumenschein GR, Jr., Antonia SJ, Dorange C, Harbison CT, Graf FF, Brahmer JR: Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. *N Engl J Med* 373:1627-1639, 2015
 56. Bottet F, Peyronnet B, Game X, Manunta A, Ruffion A, Perrouin-Verbe B, Reiss B, Previnaire J, Tournebise H, Bernuz B, Lenne K, Lechevallier E, Karsenty G: [Not Available]. *Prog Urol* 25:737, 2015

57. Bougeard G, Renaux-Petel M, Flaman JM, Charbonnier C, Fermey P, Belotti M, Gauthier-Villars M, Stoppa-Lyonnet D, Consolino E, Brugieres L, Caron O, Benusiglio PR, Bressac-de PB, Bonadona V, Bonaiti-Pellie C, Tinat J, Baert-Desurmont S, Frebourg T: Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers. *J Clin Oncol* 33:2345-2352, 2015
58. Bourlière M, Bronowicki JP, de Ledinghen V, Hézode C, Zoulim F, Mathurin P, Tran A, Larrey DG, Ratzu V, Alric L, Hyland RH, Jiang D, Doehle B, Pang PS, Symonds WT, Subramanian GM, McHutchison JG, Marcellin P, Habersetzer F, Guyader D, Grangé JD, Loustaud-Ratti V, Serfaty L, Metivier S, Leroy V, Abergel A, Pol S. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). *Lancet Infect Dis*. 2015 Apr;15(4):397-404.
59. Boussuges A, Chaumet G, Poirette L: Interest of ultrasonographic assessment of diaphragmatic function in cardiac rehabilitation center: a case report. *Medicine (Baltimore)* 94:e801, 2015
60. Boyd A, Moh R, Gabillard D, le Carrou J, Danel C, Anglaret X, Eholie SP, Maylin S, Delaugerre C, Zoulim F, Girard PM, Lacombe K; ANRS 12240 VarBVA study. Low risk of lamivudine-resistant HBV and hepatic flares in treated HIV-HBV co-infected patients from Côte d'Ivoire. *Antivir Ther*. 2015 Apr 8.
61. Brahimi-Horn MC, Lacas-Gervais S, Adaixo R, Ilc K, Rouleau M, Notte A, Dieu M, Michiels C, Voeltzel T, Maguer-Satta V, Pelletier J, Ilie M, Hofman P, Manoury B, Schmidt A, Hiller S, Pouyssegur J, Mazure NM: Local mitochondrial-endolysosomal microfusion cleaves voltage-dependent anion channel 1 to promote survival in hypoxia. *Mol Cell Biol* 35:1491-1505, 2015
62. Brahmi M, Alberti L, Dufresne A, Ray-Coquard I, Cassier P, Meeus P, Decouvelaere AV, Ranchere-Vince D, Blay JY: KIT exon 10 variant (c.1621 A > C) single nucleotide polymorphism as predictor of GIST patient outcome. *BMC Cancer* 15:780, 2015
63. Brahmi M, Thiesse P, Ranchere D, Moggetti T, Pinson S, Renard C, Decouvelaere AV, Blay JY, Combemale P: Diagnostic Accuracy of PET/CT-Guided Percutaneous Biopsies for Malignant Peripheral Nerve Sheath Tumors in Neurofibromatosis Type 1 Patients. *PLoS One* 10:e0138386, 2015
64. Braun T, Cereja S, Chevret S, Raffoux E, Beaumont M, Detourmignies L, Pigneux A, Thomas X, Bordessoule D, Guerci A, Lamy T, Recher C, Poire X, Tournilhac O, Spertini O, Chomienne C, Degos L, Dombret H, Ades L, Fenaux P. Evolving characteristics and outcome of secondary acute promyelocytic leukemia (APL): A prospective analysis by the French-Belgian-Swiss APL group. *Cancer*, 2015; 121(14): 2393-2399.

65. Brieau B, Lepere C, Walter T, Lecomte T, Guimbaud R, Manfredi S, Tougeron D, Desseigne F, Lourenco N, Afchain P, El HF, Terris B, Rougier P, Coriat R: Radiochemotherapy Versus Surgery in Nonmetastatic Anorectal Neuroendocrine Carcinoma: A Multicenter Study by the Association des Gastro-Enterologues Oncologues. *Medicine (Baltimore)* 94:e1864, 2015
66. Brisou G, Manzoni D, Dalle S, Felman P, Morel D, Boubaya M, Magaud JP, Baseggio L. Alarms and parameters generated by hematology analyzer: new tools to predict and quantify circulating Sezary cells. *J Clin Lab Anal*, 2015; 29(2): 153-161.
67. Britel M, Foray N, Préau M. Personalized medicine in radiotherapy: practitioners' perception. *Sante Publique*. 2015 Sep-Oct;27(5):669-77.
68. Brodowicz T, Liegl-Atzwager B, Tresch E, Taieb S, Kramar A, Gruenwald V, Vanseymortier M, Clisant S, Blay JY, Le CA, Penel N: Study protocol of REGOSARC trial: activity and safety of regorafenib in advanced soft tissue sarcoma: a multinational, randomized, placebo-controlled, phase II trial. *BMC Cancer* 15:127, 2015
69. Bui-Nguyen B, Butrynski JE, Penel N, Blay JY, Isambert N, Milhem M, Kerst JM, Reyners AK, Litiere S, Marreaud S, Collin F, van der Graaf WT: A phase IIb multicentre study comparing the efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated soft tissue sarcoma: the TRUSTS trial. *Eur J Cancer* 51:1312-1320, 2015
70. Buja A, Martines D, Lobello S, Vinelli A, Bardelle G, Lopatriello S, De LF, Perrier L, Baldo V: A cost-consequence analysis of hepatitis B screening in an immigrant population. *Ann Ist Super Sanita* 51:327-335, 2015
71. Bureau E, Pellegrini I, Nogues C, Lasset C, Julian-Reynier C: "Maybe they have found something new" participants' views on returning cohort psychosocial survey results. *Health Expect* 18:2425-2436, 2015
72. Bylicki O, Gan HK, Joly F, Maillet D, You B, Peron J: Poor patient-reported outcomes reporting according to CONSORT guidelines in randomized clinical trials evaluating systemic cancer therapy. *Ann Oncol* 26:231-237, 2015
73. Bylicki O, Rouviere D, Cassier P, Chalabreysse L, Levard A, Maury JM, Margery J, Blay JY, Mazieres J, Girard N: Assessing the multimodal management of advanced solitary fibrous tumors of the pleura in a routine practice setting. *J Thorac Oncol* 10:309-315, 2015
74. Campa D, Martino A, Varkonyi J, Lesueur F, Jamroziak K, Landi S, Jurczynszyn A, Marques H, Andersen V, Jurado M, Brenner H, Petrini M, Vogel U, Garcia-Sanz R, Buda G, Gemignani F, Rios R, Vangsted AJ, Dumontet C, Martinez-Lopez J, Moreno MJ, Stepien A, Watek M, Moreno V, Dieffenbach AK, Rossi AM, Butterbach K, Jacobsen SE, Goldschmidt H, Sainz J, Hillengass J, Orciuolo

- E, Dudzinski M, Weinhold N, Reis RM, Canzian F. Risk of multiple myeloma is associated with polymorphisms within telomerase genes and telomere length. *Int J Cancer*, 2015; 136(5): E351-358.
75. Cannas G, Fattoum J, Boukhit M, Thomas X. Economic analysis of blood product transfusions according to the treatment of acute myeloid leukemia in the elderly. *Transfus Clin Biol*, 2015; 22(5-6): 341-347.
 76. Cannas G, Fattoum J, Raba M, Dolange H, Barday G, Francois M, Elhamri M, Salles G, Thomas X. Transfusion dependency at diagnosis and transfusion intensity during initial chemotherapy are associated with poorer outcomes in adult acute myeloid leukemia. *Ann Hematol*, 2015; 94(11): 1797-1806.
 77. Cannas G, Thomas X. Supportive care in patients with acute leukaemia: historical perspectives. *Blood Transfus*, 2015; 13(2): 205-220.
 78. Carrabin N, Dammacco MA, Beurrier F, Chopin N, Klingler S, Ferraioli D, Faure C: [Axillary lymph node dissection after breast reconstruction by pedicled Latissimus dorsi: Operative steps and outcomes]. *Gynecol Obstet Fertil* 43:718-721, 2015
 79. Carrabin N, Vermersh C, Faure C, Dammacco MA, Delay E, Ho QC: [Tolerance of latissimus dorsi without implant to radiotherapy in immediate breast reconstruction]. *Ann Chir Plast Esthet* 60:500-505, 2015
 80. Carretier J, Boyle H, Duval S, Philip T, Laurence V, Stark DP, Berger C, Marec-Berard P, Fervers B: A Review of Health Behaviors in Childhood and Adolescent Cancer Survivors: Toward Prevention of Second Primary Cancer. *J Adolesc Young Adult Oncol* 2015
 81. Casali PG, Bruzzi P, Bogaerts J, Blay JY: Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper. *Ann Oncol* 26:300-306, 2015
 82. Casali PG, Le CA, Poveda VA, Kotasek D, Rutkowski P, Hohenberger P, Fumagalli E, Judson IR, Italiano A, Gelderblom H, Adenis A, Hartmann JT, Duffaud F, Goldstein D, Broto JM, Gronchi A, Dei Tos AP, Marreaud S, van der Graaf WT, Zalberg JR, Litiere S, Blay JY: Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas. *J Clin Oncol* 33:4276-4283, 2015
 83. Casey SC, Vaccari M, Al-Mulla F, Al-Temaimi R, Amedei A, Barcellos-Hoff MH, Brown D, Chapellier M, Christopher J, Curran C, Forte S, Hamid RA, Heneberg P, Koch DC, Krishnakumar PK, Laconi E, Maguer-Satta V, Marongiu

- F, Memeo L, Mondello C, Raju J, Roman J, Roy R, Ryan E, Ryeom S, Salem HK, Scovassi I, Singh N, Soucek L, Vermeulen L, Whitfield JR, Woodrick J, Colacci A, Bisson WH and Felsher DW* (2014) Assessing the Carcinogenic Potential of Environmental Chemicals: The Tumor Microenvironment. Carcinogenesis, In press
84. Cassier PA, Italiano A, Gomez-Roca CA, Le TC, Toulmonde M, Cannarile MA, Ries C, Brillouet A, Muller C, Jegg AM, Broske AM, Dembowski M, Bray-French K, Freilinger C, Meneses-Lorente G, Baehner M, Harding R, Ratnayake J, Abiraj K, Gass N, Noh K, Christen RD, Ukarma L, Bompas E, Delord JP, Blay JY, Ruttinger D: CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study. *Lancet Oncol* 16:949-956, 2015
 85. Cellupica M: [Doctor-nurse delegation of the insertion of central venous lines]. *Rev Infirm* 207:36-39, 2015
 86. Cettier J, Bayle ML, Beranger R, Billoir E, Nuckols JR, Combourieu B, Fervers B: Efficiency of wipe sampling on hard surfaces for pesticides and PCB residues in dust. *Sci Total Environ* 505:11-21, 2015
 87. Chabrol E, Thepaut M, Dezutter-Dambuyant C, Vives C, Marcoux J, Kahn R, Valladeau-Guilemond J, Vachette P, Durand D, Fieschi F: Alteration of the langerin oligomerization state affects Birbeck granule formation. *Biophys J* 108:666-677, 2015
 88. Chalandon Y, Thomas X, Hayette S, Cayuela JM, Abbal C, Huguet F, Raffoux E, Leguay T, Rousselot P, Lepretre S, Escoffre-Barbe M, Maury S, Berthon C, Tavernier E, Lambert JF, Lafage-Pochitaloff M, Lheritier V, Chevret S, Ifrah N, Dombret H. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. *Blood*, 2015; 125(24): 3711-3719.
 89. Chalayer E, Bachy E, Occelli P, Weiler L, Faurie P, Ghesquieres H, Pavic M, Broussolle C, Seve P: Sarcoidosis and lymphoma: a comparative study. *QJM* 108:871-878, 2015
 90. Chapellier M, Bachelard-Cascales E, Schmidt X, Clement F, Treilleux I, Delay E, Jammot A, Menetrier-Caux C, Pochon G, Besancon R, Voeltzel T, Caron de FC, Caux C, Blay JY, Iggo R, Maguer-Satta V: Disequilibrium of BMP2 levels in the breast stem cell niche launches epithelial transformation by overamplifying BMPR1B cell response. *Stem Cell Reports* 4:239-254, 2015
 91. Charuworn P, Hengen PN, Aguilar Schall R, Dinh P, Ge D, Corsa A, Reesink HW, Zoulim F, Kitrinis KM. Baseline interpatient hepatitis B viral diversity differentiates HBsAg outcomes in patients treated with tenofovir disoproxil fumarate. *J Hepatol.* 2015 May;62(5):1033-9.

92. Chettab K, Roux S, Mathe D, Cros-Perrial E, Lafond M, Lafon C, Dumontet C, Mestas JL. Spatial and Temporal Control of Cavitation Allows High In Vitro Transfection Efficiency in the Absence of Transfection Reagents or Contrast Agents. *PLoS One*, 2015; 10(8): e0134247.
93. Chevallier P, Eugene T, Robillard N, Isnard F, Nicolini F, Escoffre-Barbe M, Huguet F, Hunault M, Marcais A, Gaschet J, Cherel M, Guillaume T, Delaunay J, Peterlin P, Eveillard M, Thomas X, Ifrah N, Lapusan S, Bodet-Milin C, Barbet J, Faivre-Chauvet A, Ferrer L, Bene MC, Le Houerou C, Goldenberg DM, Wegener WA, Kraeber-Bodere F. (90)Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study. *Lancet Haematol*, 2015; 2(3): e108-117.
94. Chien WW, Catallo R, Chebel A, Baranger L, Thomas X, Bene MC, Gerland LM, Schmidt A, Beldjord K, Klein N, Escoffre-Barbe M, Leguay T, Huguet F, Larosa F, Hayette S, Plesa A, Ifrah N, Dombret H, Salles G, Chassevent A, Ffrench M. The p16(INK4A)/pRb pathway and telomerase activity define a subgroup of Ph+ adult Acute Lymphoblastic Leukemia associated with inferior outcome. *Leuk Res*, 2015; 39(4): 453-461.
95. Cividini F, Cros-Perrial E, Pesi R, Machon C, Allegrini S, Camici M, Dumontet C, Jordheim LP, Tozzi MG. Cell proliferation and drug sensitivity of human glioblastoma cells are altered by the stable modulation of cytosolic 5'-nucleotidase II. *Int J Biochem Cell Biol*, 2015; 65:222-229.
96. Cividini F, Pesi R, Chaloin L, Allegrini S, Camici M, Cros-Perrial E, Dumontet C, Jordheim LP, Tozzi MG. The purine analog fludarabine acts as a cytosolic 5'-nucleotidase II inhibitor. *Biochem Pharmacol*, 2015; 94(2): 63-68.
97. Cividini F, Tozzi MG, Galli A, Pesi R, Camici M, Dumontet C, Jordheim LP, Allegrini S. Cytosolic 5'-nucleotidase II interacts with the leucine rich repeat of NLR family member Ipaf. *PLoS One*, 2015; 10(3): e0121525.
98. Clapp GD, Lepoutre T, El CR, Bernard S, Ruby J, Labussiere-Wallet H, Nicolini FE, Levy D: Implication of the Autologous Immune System in BCR-ABL Transcript Variations in Chronic Myelogenous Leukemia Patients Treated with Imatinib. *Cancer Res* 75:4053-4062, 2015
99. Classe JM, Glehen O, Decullier E, Bereder JM, Msika S, Lorimier G, Abboud K, Meeus P, Ferron G, Quenet F, Marchal F, Gouy S, Pomel C, Pocard M, Guyon F, Bakrin N: Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for First Relapse of Ovarian Cancer. *Anticancer Res* 35:4997-5005, 2015
100. Claude L, Faure-Contier C, Frappaz D, Mottolese C, Carrie C: Radiation therapy in pediatric pineal tumors. *Neurochirurgie* 61:212-215, 2015

101. Claude L, Laprie A: [Which dose constraints on which critical organs in paediatric radiation therapy?]. *Cancer Radiother* 19:484-488, 2015
102. Clavel AH, Monnin P, Letang JM, Verdun FR, Darbon A: Characterising the EOS slot-scanning system with the effective detective quantum efficiency. *Radiat Prot Dosimetry* 2015
103. Clemenceau B, Valsesia-Wittmann S, Jallas AC, Vivien R, Rousseau R, Marabelle A, Caux C, Vie H: In Vitro and In Vivo Comparison of Lymphocytes Transduced with a Human CD16 or with a Chimeric Antigen Receptor Reveals Potential Off-Target Interactions due to the IgG2 CH2-CH3 CAR-Spacer. *J Immunol Res* 2015:482089, 2015
104. Clement F, Zhu HH, Gao WQ, Delay E, Maguer-Satta V: Quantifying Epithelial Early Common Progenitors from Long-Term Primary or Cell Line Sphere Culture. *Curr Protoc Stem Cell Biol* 35:1E-8, 2015
105. Coens C, van der Graaf WT, Blay JY, Chawla SP, Judson I, Sanfilippo R, Manson SC, Hodge RA, Marreaud S, Prins JB, Lugowska I, Litiere S, Bottomley A: Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy-a European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072). *Cancer* 121:2933-2941, 2015
106. Combaret V, Iacono I, Bellini A, Brejon S, Bernard V, Marabelle A, Coze C, Pierron G, Lapouble E, Schleiermacher G, Blay JY: Detection of tumor ALK status in neuroblastoma patients using peripheral blood. *Cancer Med* 4:540-550, 2015
107. Combaret V, Iacono I, Bellini A, Bréjon S, Bernard V, Marabelle A, Coze C, Pierron G, Lapouble E, Schleiermacher G, Blay JY. Detection of tumor ALK status in neuroblastoma patients using peripheral blood. *Cancer Med*. 2015 Apr;4(4):540-50. Erratum in: *Cancer Med*. 2016 Feb;5(2):386.
108. Cortes J, Dieras V, Ro J, Barriere J, Bachelot T, Hurvitz S, Le RE, Espie M, Kim SB, Schneeweiss A, Sohn JH, Nabholz JM, Kellokumpu-Lehtinen PL, Taguchi J, Piantini F, Ciruelos E, Bono P, Ould-Kaci M, Roux F, Joensuu H: Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial. *Lancet Oncol* 16:1700-1710, 2015
109. Costa S, Byrne M, Pissaloux D, Haddad V, Paindavoine S, Thomas L, Aubin F, Lesimple T, Grange F, Bonniaud B, Mortier L, Mateus C, Dreno B, Balme B, Vergier B, de la Fouchardiere A. Melanomas Associated With Blue Nevi or

- Mimicking Cellular Blue Nevi: Clinical, Pathologic, and Molecular Study of 11 Cases Displaying a High Frequency of GNA11 Mutations, BAP1 Expression Loss, and a Predilection for the Scalp. *Am J Surg Pathol*. 2015 Dec 5. [Epub ahead of print]
110. Couder F, Schmitt C, Treilleux I, Tredan O, Faure C, Carrabin N, Beurrier F, Chopin N: [Axillary lymph node metastases with an occult breast: About 16 cases from a cohort of 7770 patients]. *Gynecol Obstet Fertil* 43:588-592, 2015
 111. Couderc C, Bollard J, Coute Y, Massoma P, Poncet G, Lepinasse F, Hervieu V, Gadot N, Sanchez JC, Scoazec JY, Diaz JJ, Roche C: Mechanisms of local invasion in enteroendocrine tumors: identification of novel candidate cytoskeleton-associated proteins in an experimental mouse model by a proteomic approach and validation in human tumors. *Mol Cell Endocrinol* 399:154-163, 2015
 112. Coudurier J, Ho QC, Ismail M, Dlimi C, Tourasse C, Delay E: [Long-term outcome of lipomodelling in Poland's syndrome: about our first case with an eleven-years' follow-up]. *Ann Chir Plast Esthet* 60:65-69, 2015
 113. Couturier MA, Huguet F, Chevallier P, Suarez F, Thomas X, Escoffre-Barbe M, Cacheux V, Pignon JM, Bonmati C, Sanhes L, Bories P, Daguindau E, Dorvaux V, Reman O, Frayfer J, Orvain C, Lheritier V, Ifrah N, Dombret H, Hunault-Berger M, Tanguy-Schmidt A. Cerebral venous thrombosis in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma during induction chemotherapy with l-asparaginase: The GRAALL experience. *Am J Hematol*, 2015; 90(11): 986-991.
 114. Cox DG, Heudel PE, Tredan O, Bachelot T: Therogenetics: transferring GWAS technology to the clinic. *Mutagenesis* 30:213-215, 2015
 115. Cox DG, Puisieux A. Les Entretiens Jacques Cartier Symposium 4--targeted cancer therapies: stakes and prospects for patients. *Mutagenesis*. 2015 Mar;30(2):167-8.
 116. Crucis A, Richer W, Brugieres L, Bergeron C, Marie-Cardine A, Stephan JL, Girard P, Corradini N, Munzer M, Lacour B, Minard-Colin V, Sarnacki S, Ranchere-Vince D, Orbach D, Bourdeaut F: Rhabdomyosarcomas in children with neurofibromatosis type I: A national historical cohort. *Pediatr Blood Cancer* 62:1733-1738, 2015
 117. Cuny F, Babin E, Lacau-Saint-Guily J, Baujat B, Bensadoun R, Bozec A, Chevalier D, Choussy O, Deneuve S, Fakhry N, Guigay J, Makeieff M, Merol JC, Mouawad F, Pavillet J, Rebiere C, Righini C, Sostras MC, Tournaille M, Vergez S: French Society of ENT (SFORL) guidelines for care pathway organization in head and neck oncology (short version). Early management of head and neck cancer. *Eur Ann Otorhinolaryngol Head Neck Dis* 132:205-208, 2015

118. Cutuli B, Dalenc F, Cottu PH, Gligorov J, Guastalla JP, Petit T, Amrate A: Impact of screening on clinicopathological features and treatment for invasive breast cancer: results of two national surveys. *Cancer Radiother* 19:295-302, 2015
119. da Costa AN., Plymoth A., Santos-Silva D., Ortiz-Cuaran S., Camey S., Guilloreau P., Sangrajrang S., Khuhaprema T., Mendy M., Lesi OA., Chang HK., Oh JK., Lee DH., Shin HR., Kirk GD., Merle P., Beretta L. and Hainaut P. (2015). Osteopontin and latent-TGF β binding-protein 2 as potential diagnostic markers for HBV-related hepatocellular carcinoma. *Int. J. Cancer*, 136, 172-181.
120. Damaj G, Ivanoff S, Coso D, Ysaebert L, Choquet S, Houillier C, Parcelier A, Abarah W, Marjanovic Z, Gressin R, Garidi R, Diouf M, Gac AC, Dupuis J, Troussard X, Morschhauseur F, Ghesquieres H, Soussain C: Concomitant systemic and central nervous system non-Hodgkin lymphoma: the role of consolidation in terms of high dose therapy and autologous stem cell transplantation. A 60-case retrospective study from LYSA and the LOC network. *Haematologica* 100:1199-1206, 2015
121. Damiola F, Schultz I, Barjhoux L, Sornin V, Dondon MG, Eon-Marchais S, Marcou M, Caron O, Gauthier-Villars M, de PA, Luporsi E, Berthet P, Delnatte C, Bonadona V, Maugard C, Pujol P, Lasset C, Longy M, Bignon YJ, Fricker JP, Andrieu N, Sinilnikova OM, Stoppa-Lyonnet D, Mazoyer S, Muller D: Mutation analysis of PALB2 gene in French breast cancer families. *Breast Cancer Res Treat* 154:463-471, 2015
122. d'Amore F, Gaulard P, Trümper L, Corradini P, Kim WS, Specht L, Bjerregaard Pedersen M, Ladetto M; ESMO Guidelines Committee. Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2015 Sep;26 Suppl 5:v108-15.
123. de Charry F, Sadoune K, Sebban C, Rey P, de PA, Nicolas-Virelizier E, Belhabri A, Ghesquieres H, Ninet J, Faurie P: [Association of lymphoma and granulomatosis: A case series]. *Rev Med Interne* 2015
124. De La Fouchardiere A, Cabaret O, Petre J, Aydin S, Leroy A, de PP, Pissaloux D, Haddad V, Bressac-de PB, Janin N: Primary leptomeningeal melanoma is part of the BAP1-related cancer syndrome. *Acta Neuropathol* 129:921-923, 2015
125. De La Fouchardiere A, Cabaret O, Savin L, Combemale P, Schwartz H, Penet C, Bonadona V, Soufir N, Bressac-de PB: Germline BAP1 mutations predispose also to multiple basal cell carcinomas. *Clin Genet* 88:273-277, 2015
126. de la Fouchardiere C: Targeted treatments of radio-iodine refractory differentiated thyroid cancer. *Ann Endocrinol (Paris)* 76:1S34-1S39, 2015
127. de Laplanche E, Boudria A, Dacheux E, Vincent A, Gadot N, Assade F, Le Corf K, Leroy X, Mège Lechevallier F, Eymin B, Dalla Venezia N, Simonnet H. Low

- glucose microenvironment of normal kidney cells stabilizes a subset of messengers involved in angiogenesis. *Physiol Rep*, 2015, 19;3(1).
128. de Léotoing L, Combemale P, Fernandes J, Bregman B, Amaz C, Vainchtock A, Gaudin A: An Assessment of The Hospitalization Costs of Melanoma in France in the Advanced/Metastatic Setting: the Melissa Study (Melanoma in Hospital Costs Assessment). *Value Health* 18:A447, 2015
 129. De Parisot A, Puechal X, Langrand C, Raverot G, Gil H, Perard L, Le Guenno G, Berthier S, Tschirret O, Eschard JP, Vinzio S, Guillevin L, Seve P. Pituitary involvement in granulomatosis with polyangiitis: report of 9 patients and review of the literature. *Medicine (Baltimore)*, 2015; 94(16): e748.
 130. de Ravel MR, Alameh G, Melikian M, Mahiout Z, Emptoz-Bonneton A, Matera EL, Lomberget T, Barret R, Rocheblave L, Walchshofer N, Beltran S, El JL, Mappus E, Grenot C, Pugeat M, Dumontet C, Le BM, Cuilleron CY: Synthesis of new steroidal inhibitors of P-glycoprotein-mediated multidrug resistance and biological evaluation on K562/R7 erythroleukemia cells. *J Med Chem* 58:1832-1845, 2015
 131. Deauvieu F, Ollion V, Doffin AC, Achard C, Fonteneau JF, Verronese E, Durand I, Ghittoni R, Marvel J, Dezutter-Dambuyant C, Walzer T, Vie H, Perrot I, Goutagny N, Caux C, Valladeau-Guilemond J: Human natural killer cells promote cross-presentation of tumor cell-derived antigens by dendritic cells. *Int J Cancer* 136:1085-1094, 2015
 132. Debarbieux S, Gaspar R, Depaepe L, Dalle S, Balme B, Thomas L. Intraoperative diagnosis of nonpigmented nail tumours with ex vivo fluorescence confocal microscopy: 10 cases. *Br J Dermatol*, 2015; 172(4): 1037-1044.
 133. Decoster L, Van PK, Mohile S, Wedding U, Basso U, Colloca G, Rostoft S, Overcash J, Wildiers H, Steer C, Kimmick G, Kanesvaran R, Luciani A, Terret C, Hurria A, Kenis C, Audisio R, Extermann M: Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendationsdagger. *Ann Oncol* 26:288-300, 2015
 134. Decouvelaere AV: [Immunohistochemistry in the diagnosis of sarcomas]. *Ann Pathol* 35:98-106, 2015
 135. Defferrari R, Mazzocco K, Ambros IM, Ambros PF, Bedwell C, Beiske K, Benard J, Berbegall AP, Bown N, Combaret V, Couturier J, Erminio G, Gambini C, Garaventa A, Gross N, Haupt R, Kohler J, Jeison M, Lunec J, Marques B, Martinsson T, Noguera R, Parodi S, Schleiermacher G, Tweddle DA, Valent A, Van RN, Vicha A, Villamon E, Tonini GP: Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification. *Br J Cancer* 112:290-295, 2015

136. Defourny N, Perrier L, Dunscombe P, Grau C, Lievens Y: The Cost of Radiotherapy: What Do We Know? a Systematic Search of the Literature Between 1981 and 2015. *Value Health* 18:A445, 2015
137. Delay E, Guerid S: The Role of Fat Grafting in Breast Reconstruction. *Clin Plast Surg* 42:315-23, vii, 2015
138. Delgrange E, Vasiljevic A, Wierinckx A, François P, Jouanneau E, Raverot G, Trouillas J. Expression of estrogen receptor alpha is associated with prolactin pituitary tumor prognosis and supports the sex-related difference in tumor growth. *Eur J Endocrinol*. 2015 Jun;172(6):791-801
139. Delolme F, Anastasi C, Alcaraz LB, Mendoza V, Vadon-Le Goff S, Talantikite M, Capomaccio R, Mevaere J, Fortin L, Mazzocut D, Damour O, Zanella-Cléon I, Hulmes DJ, Overall CM, Valcourt U, Lopez-Casillas F, Moali C. Proteolytic control of TGF- β co-receptor activity by BMP-1/tolloid-like proteases revealed by quantitative iTRAQ proteomics. *Cell Mol Life Sci*. 2015; 72(5): 1009-27
140. Delpon G, Chiavassa S, Supiot S, Boutry C, Darreon J, Desrousseaux J, Lafay F, Leysalle A, de CR: [Image-guided radiotherapy: Overview of devices and practice in France in 2015]. *Cancer Radiother* 19:501-507, 2015
141. Deneuve S, Babin E, Lacau-St-Guily J, Baujat B, Bensadoun RJ, Bozec A, Chevalier D, Choussy O, Cuny F, Fakhry N, Guigay J, Makeieff M, Merol JC, Mouawad F, Pavillet J, Rebiere C, Righini CA, Sostras MC, Tournaille M, Vergez S: Guidelines (short version) of the French Otorhinolaryngology - Head and Neck Surgery Society (SFORL) on patient pathway organization in ENT: The therapeutic decision-making process. *Eur Ann Otorhinolaryngol Head Neck Dis* 132:213-215, 2015
142. Despierre E, Vergote I, Anderson R, Coens C, Katsaros D, Hirsch FR, Boeckx B, Varella-Garcia M, Ferrero A, Ray-Coquard I, Berns EM, Casado A, Lambrechts D, Jimeno A: Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy. *Target Oncol* 10:583-596, 2015
143. Devailly G, Grandin M, Perriaud L, Mathot P, Delcros JG, Bidet Y, Morel AP, Bignon JY, Puisieux A, Mehlen P, Dante R: Dynamics of MBD2 deposition across methylated DNA regions during malignant transformation of human mammary epithelial cells. *Nucleic Acids Res* 43:5838-5854, 2015
144. Dhedin N, Huynh A, Maury S, Tabrizi R, Beldjord K, Asnafi V, Thomas X, Chevallier P, Nguyen S, Coiteux V, Bourhis JH, Hichri Y, Escoffre-Barbe M, Reman O, Graux C, Chalandon Y, Blaise D, Schanz U, Lheritier V, Cahn JY, Dombret H, Ifrah N. Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia. *Blood*, 2015; 125(16): 2486-2496.

145. Di Giannatale A, Frezza AM, Le Deley MC, Marec-Berard P, Benson C, Blay JY, Bui B, Judson I, Oberlin O, Whelan J, Gaspar N: Primary cutaneous and subcutaneous Ewing sarcoma. *Pediatr Blood Cancer* 62:1555-1561, 2015
146. Dieras V, Wildiers H, Jassem J, Dirix LY, Guastalla JP, Bono P, Hurvitz SA, Goncalves A, Romieu G, Limentani SA, Jerusalem G, Lakshmaiah KC, Roche H, Sanchez-Rovira P, Pienkowski T, Segui Palmer MA, Li A, Sun YN, Pickett CA, Slamon DJ: Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study. *Breast* 24:182-190, 2015
147. Dombret H, Thomas X, Chevallier P, Nivot E, Reitan J, Barber BL, Barlev A, Mohty M. Healthcare Burden and Economic Cost of Hospitalisation During Chemotherapy for Adult Patients with Ph-Negative B-Precursor Relapsed or Refractory (R/R) Acute Lymphoblastic Leukaemia (All) in France. *Value Health*, 2015; 18(7): A443.
148. Duclaux-Loras R, Lachaux A, Guibaud L, Bertrand Y: [Is alfa-interferon still current in the management of Kasabach-Merritt syndrome?]. *Arch Pediatr* 22:523-527, 2015
149. Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goéré D, Seufferlein T, Haustermans K, Van Laethem JL, Conroy T, Arnold D; ESMO Guidelines Committee. Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2015 Sep;26 Suppl 5:v56-68.
150. Duffaud F, Ray-Coquard I, Salas S, Pautier P: Recent advances in understanding and managing leiomyosarcomas. *F1000Prime Rep* 7:55, 2015
151. Duffaud F, Sleijfer S, Litiere S, Ray-Coquard I, Le CA, Papai Z, Judson I, Schoffski P, Chawla SP, Dewji R, Marreaud S, Verweij J, van der Graaf WT: Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trials. *Eur J Cancer* 51:2615-2623, 2015
152. Dufresne A, Cassier P, Heudel P, Pissaloux D, Wang Q, Blay JY, Ray-Coquard I: [Molecular biology of sarcoma and therapeutic choices]. *Bull Cancer* 102:6-16, 2015
153. Dufresne A, Paturel M, Alberti L, Philippon H, Duc A, Decouvelaere AV, Cassier P, Blay JY: Prediction of desmoid tumor progression using miRNA expression profiling. *Cancer Sci* 106:650-655, 2015

154. Dummer R, Hauschild A, Lindenblatt N, Pentheroudakis G, Keilholz U; ESMO Guidelines Committee. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2015 Sep;26 Suppl 5:v126-32
155. Duong MN, Cleret A, Matera EL, Chettab K, Mathe D, Valsesia-Wittmann S, Clemenceau B, Dumontet C: Adipose cells promote resistance of breast cancer cells to trastuzumab-mediated antibody-dependent cellular cytotoxicity. *Breast Cancer Res* 17:57, 2015
156. Duong MN, Matera EL, Mathe D, Evesque A, Valsesia-Wittmann S, Clemenceau B, Dumontet C. Effect of kinase inhibitors on the therapeutic properties of monoclonal antibodies. *MAbs*, 2015; 7(1): 192-198.
157. Dupre A, Hitier M, Peyrat P, Chen Y, Meeus P, Rivoire M: Associating portal embolization and artery ligation to induce rapid liver regeneration in staged hepatectomy. *Br J Surg* 102:1541-1550, 2015
158. Dupre A, Melodelima D, Perol D, Chen Y, Vincenot J, Chapelon JY, Rivoire M: First clinical experience of intra-operative high intensity focused ultrasound in patients with colorectal liver metastases: a phase I-IIa study. *PLoS One* 10:e0118212, 2015
159. Dupre A, Perol D, Rivoire M: Reply to Letter: "Adhesiolysis and Adhesion Prevention in 2-Stage Surgery". *Ann Surg* 261:e170-e171, 2015
160. Dupuis J, Morschhauser F, Ghesquieres H, Tilly H, Casasnovas O, Thieblemont C, Ribrag V, Bossard C, Le BF, Bachy E, Hivert B, Nicolas-Virelizier E, Jardin F, Bastie JN, Amorim S, Lazarovici J, Martin A, Coiffier B: Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study. *Lancet Haematol* 2:e160-e165, 2015
161. Dupuis-Maurin V, Brinza L, Baguet J, Plantamura E, Schicklin S, Chambion S, Macari C, Tomkowiak M, Deniaud E, Leverrier Y, Marvel J*, Michallet MC*. (*co-last authorship) (2015) Overexpression of the transcription factor Sp1 activates the OAS-RNase L-RIG-I pathway. *Plos One*. 10(3):e0118551.
162. Duraes FV, Lippens C, Steinbach K, Dubrot J, Brighthouse D, Bendriss-Vermare N, Issazadeh-Navikas S, Merkler D, Hugues S. pDC therapy induces recovery from EAE by recruiting endogenous pDC to sites of CNS inflammation. *J Autoimmun*. 2016 Feb;67:8-18.
163. Durif-Bruckert C, Roux P, Morelle M, Mignotte H, Faure C, Moumjid-Ferdjaoui N: Shared decision-making in medical encounters regarding breast cancer treatment: the contribution of methodological triangulation. *Eur J Cancer Care (Engl)* 24:461-472, 2015

164. Duval S, Carretier J, Boyle H, Philip T, Berger C, Marec-Berard P, Fervers B: [Life style and occupational factors and prevention of second primary cancers after childhood and adolescent cancer: Current state of knowledge]. *Bull Cancer* 102:665-673, 2015
165. Edmond V, Dufour F, Poiroux G, Shoji K, Malleter M, Fouque A, Tauzin S, Rimokh R, Sergent O, Penna A, Dupuy A, Levade T, Theret N, Micheau O, Segui B, Legembre P: Downregulation of ceramide synthase-6 during epithelial-to-mesenchymal transition reduces plasma membrane fluidity and cancer cell motility. *Oncogene* 34:996-1005, 2015
166. Eichhorst B, Robak T, Montserrat E, Ghia P, Hillmen P, Hallek M, Buske C; ESMO Guidelines Committee. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2015 Sep;26 Suppl 5:v78-84.
167. Eisinger F, Morère JF, Touboul C, Pivot X, Coscas Y, Blay JY, Lhomel C, Viguier J. Prostate cancer screening: contrasting trends. *Cancer Causes Control.* 2015 Jun;26(6):949-52
168. Eisinger F, Viguier J, Touboul C, Coscas Y, Pivot X, Blay JY, Lhomel C, Morère JF. Social stratification, risk factor prevalence and cancer screening attendance. *Eur J Cancer Prev.* 2015 Jun;24 Suppl:S77-81
169. El Kanawati W, Letang JM, Dauvergne D, Pinto M, Sarrut D, Testa E, Freud N: Monte Carlo simulation of prompt gamma-ray emission in proton therapy using a specific track length estimator. *Phys Med Biol* 60:8067-8086, 2015
170. Eleveld TF, Oldridge DA, Bernard V, Koster J, Daage LC, Diskin SJ, Schild L, Bentahar NB, Bellini A, Chicard M, Lapouble E, Combaret V, Legoix-Ne P, Michon J, Pugh TJ, Hart LS, Rader J, Attiyeh EF, Wei JS, Zhang S, Naranjo A, Gastier-Foster JM, Hogarty MD, Asgharzadeh S, Smith MA, Guidry Auvil JM, Watkins TB, Zwijnenburg DA, Ebus ME, van SP, Hakkert A, van WE, van der Schoot CE, Westerhout EM, Schulte JH, Tytgat GA, Dolman ME, Janoueix-Lerosey I, Gerhard DS, Caron HN, Delattre O, Khan J, Versteeg R, Schleiermacher G, Molenaar JJ, Maris JM: Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. *Nat Genet* 47:864-871, 2015
171. Espiard S, Savagner F, Flamant F, Vlaeminck-Guillem V, Guyot R, Munier M, d'Herbomez M, Bourguet W, Pinto G, Rose C, Rodien P, Wemeau JL: A Novel Mutation in THRA Gene Associated With an Atypical Phenotype of Resistance to Thyroid Hormone. *J Clin Endocrinol Metab* 100:2841-2848, 2015
172. Etienne-Grimaldi MC, Boyer JC, Thomas F, Quaranta S, Picard N, Loriot MA, Narjoz C, Poncet D, Gagnieu MC, Ged C, Broly F, Le M, V, Bouquie R, Gaub MP, Philibert L, Ghiringhelli F, Le GC: UGT1A1 genotype and irinotecan

- therapy: general review and implementation in routine practice. *Fundam Clin Pharmacol* 29:219-237, 2015
173. Ezzalfani M, Dugue A, Mollevi C, Pulido M, Bonnetain F, Filleron T, Gal J, Gauthier M, Le Deley MC, Le TC, Medioni J, Nguyen JM, Chabaud S, Teixeira L, Thivat E, You B, Kramar A, Paoletti X: [The role of the expansion cohort in phase I trials in oncology: guidelines of the phase I HUB]. *Bull Cancer* 102:73-82, 2015
 174. Falk AT, Moureau-Zabotto L, Ouali M, Penel N, Italiano A, Bay JO, Olivier T, Sunyach MP, Boudou-Roquette P, Salas S, Le MC, Ducassou A, Isambert N, Kalbacher E, Pan C, Saada E, Bertucci F, Thyss A, Thariat J: Effect on survival of local ablative treatment of metastases from sarcomas: a study of the French sarcoma group. *Clin Oncol (R Coll Radiol)* 27:48-55, 2015
 175. Fargier-Voiron M, Presles B, Pommier P, Munoz A, Rit S, Sarrut D, Biston MC: Ultrasound versus Cone-beam CT image-guided radiotherapy for prostate and post-prostatectomy pretreatment localization. *Phys Med* 31:997-1004, 2015
 176. Fattoum J, Cannas G, Elhamri M, Tigaud I, Plesa A, Heiblig M, Plesa C, Wattel E, Thomas X. Effect of Age on Treatment Decision-Making in Elderly Patients With Acute Myeloid Leukemia. *Clin Lymphoma Myeloma Leuk*, 2015; 15(8): 477-483.
 177. Fauconneau A, Pham-Ledard A, Cappellen D, Frison E, Prochazkova-Carlotti M, Parrens M, Dalle S, Joly P, Viraben R, Franck F, Ingen-Housz-Oro S, Giacchero D, Jullie ML, Vergier B, Merlio JP, Beylot-Barry M. Assessment of diagnostic criteria between primary cutaneous anaplastic large-cell lymphoma and CD30-rich transformed mycosis fungoides; a study of 66 cases. *Br J Dermatol*, 2015; 172(6): 1547-1554.
 178. Faure-Contier C: Tumoral markers in tumors of the pineal region. *Neurochirurgie* 61:143-145, 2015
 179. Fayette J, Molin Y, Lavergne E, Montbarbon X, Racadot S, Poupart M, Ramade A, Zrounba P, Ceruse P, Pommier P: Radiotherapy potentiation with weekly cisplatin compared to standard every 3 weeks cisplatin chemotherapy for locoregionally advanced head and neck squamous cell carcinoma. *Drug Des Devel Ther* 9:6203-6210, 2015
 180. Febvay C, Kodjikian L, Maucourt-Boulch D, Perard L, Iwaz J, Jamilloux Y, Broussolle C, Burillon C, Seve P. Clinical features and diagnostic evaluation of 83 biopsy-proven sarcoid uveitis cases. *Br J Ophthalmol*, 2015; 99(10): 1372-1376.
 181. Ferraioli D, Chopin N, Beurrier F, Carrabin N, Buenerd A, Mathevet P: The incidence and clinical significance of the micrometastases in the sentinel lymph

- nodes during surgical staging for early endometrial cancer. *Int J Gynecol Cancer* 25:673-680, 2015
182. Ferrand M, Kirsh O, Griveau A, Vindrieux D, Martin N, Defossez PA, Bernard D: Screening of a kinase library reveals novel pro-senescence kinases and their common NF-kappaB-dependent transcriptional program. *Aging (Albany NY)* 7:986-1003, 2015
 183. Ferrari A, De Salvo GL, Brennan B, van Noesel MM, De PA, Casanova M, Francotte N, Kelsey A, Alaggio R, Oberlin O, Carli M, Ben-Arush M, Bergeron C, Merks JH, Jenney M, Stevens MC, Bisogno G, Orbach D: Synovial sarcoma in children and adolescents: the European Pediatric Soft Tissue Sarcoma Study Group prospective trial (EpSSG NRSTS 2005). *Ann Oncol* 26:567-572, 2015
 184. Ferron G, Simon L, Guyon F, Glehen O, Goere D, Elias D, Pocard M, Gladieff L, Bereder JM, Brigand C, Classe JM, Guilloit JM, Quenet F, Abboud K, Arvieux C, Bibeau F, De CC, Delroeux D, Durand-Fontanier S, Goasguen N, Gouthi L, Heyd B, Kianmanesh R, Leblanc E, Loi V, Lorimier G, Marchal F, Mariani P, Mariette C, Meeus P, Msika S, Ortega-Deballon P, Paineau J, Pezet D, Piessen G, Pirro N, Pomel C, Porcheron J, Pourcher G, Rat P, Regimbeau JM, Sabbagh C, Thibaudeau E, Torrent JJ, Tougeron D, Tuech JJ, Zinzindohoue F, Lundberg P, Herin F, Villeneuve L: Professional risks when carrying out cytoreductive surgery for peritoneal malignancy with hyperthermic intraperitoneal chemotherapy (HIPEC): A French multicentric survey. *Eur J Surg Oncol* 41:1361-1367, 2015
 185. Feurer E, Bielefeld P, Saadoun D, Seve P. Biologics in uveitis. *Rev Med Interne*, 2015; 36(2): 107-116.
 186. Fitamant J, Kottakis F, Benhamouche S, Tian HS, Chuvin N, Parachoniak CA, Nagle JM, Perera RM, Lapouge M, Deshpande V, Zhu AX, Lai A, Min B, Hoshida Y, Avruch J, Sia D, Campreciós G, McClatchey AI, Llovet JM, Morrissey D, Raj L, Bardeesy N. YAP inhibition restores hepatocyte differentiation in advanced HCC, leading to tumor regression. *Cell Rep.* 2015; Mar10.pii: S2211-1247(15)00173-4. -
 187. Fizazi K, Faivre L, Lesaunier F, Delva R, Gravis G, Rolland F, Priou F, Ferrero JM, Houede N, Mourey L, Theodore C, Krakowski I, Berdah JF, Baciuchka M, Laguerre B, Flechon A, Ravaud A, Cojean-Zelek I, Oudard S, Labourey JL, Chinet-Charrot P, Legouffe E, Lagrange JL, Linassier C, Deplanque G, Beuzeboc P, Davin JL, Martin AL, Habibian M, Laplanche A, Culine S: Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. *Lancet Oncol* 16:787-794, 2015
 188. Fizazi K, Greco FA, Pavlidis N, Daugaard G, Oien K, Pentheroudakis G; ESMO Guidelines Committee. Cancers of unknown primary site: ESMO Clinical

- Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2015 Sep;26 Suppl 5:v133-8.
189. Folliet L, Perpoint T, Pignat JC, Laurent F, Devouassoux M, Perol M, Nesme P, Guerin JC, Ernesto S, Odier L, Arpin D. Tumor-bronchial actinomycosis simulating a recurrence of lung cancer 14 years after initial treatment: A case report. *Rev Mal Respir.* 2015 May;32(5):524-9
 190. Foray N. Léon Bouchacourt (1865-1949): How an obstetrician pointed out individual radiosensitivity]. *Cancer Radiother.* 2015 Dec;19(8):752-61
 191. Foucaut AM, Berthouze SE, Touillaud M, Morelle M, Bourne-Branch, Kempf-Lepine AS, Carretier J, Perol D, Tredan O, Bachmann P, Fervers B: Deterioration of Physical Activity Level and Metabolic Risk Factors After Early-Stage Breast Cancer Diagnosis. *Cancer Nurs* 38:E1-E9, 2015
 192. Foy JP, Pickering CR, Papadimitrakopoulou VA, Jelinek J, Lin SH, William WN, Jr., Frederick MJ, Wang J, Lang W, Feng L, Zhang L, Kim ES, Fan YH, Hong WK, El-Naggar AK, Lee JJ, Myers JN, Issa JP, Lippman SM, Mao L, Saintigny P: New DNA methylation markers and global DNA hypomethylation are associated with oral cancer development. *Cancer Prev Res (Phila)* 8:1027-1035, 2015
 193. Fraison JB, Seve P, Dauphin C, Mahr A, Gomard-Mennesson E, Varron L, Pugnet G, Landron C, Roblot P, Oziol E, Chalhoub G, Galempoix JM, Humbert S, Humbert P, Sbidian E, Grange F, Bayrou O, Cathebras P, Morlat P, Epaulard O, Pavese P, Le Thi Huong D, Zoulim A, Stankovic K, Bachelez H, Smail A, Bachmeyer C, Granel B, Serratrice J, Brinchault G, Mekinian A, Costedoat-Chalumeau N, Bourgarit-Durand A, Puechal X, Guillevin L, Piram M, Kone-Paut I, Fain O. Kawasaki disease in adults: Observations in France and literature review. *Autoimmun Rev*, 2015;
 194. Francois CM, Wargnier R, Petit F, Goulvent T, Rimokh R, Treilleux I, Ray-Coquard I, Zazzu V, Cohen-Tannoudji J, Guigon CJ: 17beta-estradiol inhibits spreading of metastatic cells from granulosa cell tumors through a non-genomic mechanism involving GPER1. *Carcinogenesis* 36:564-573, 2015
 195. Frappaz D, Conter CF, Szathmari A, Valsijevic A, Mottolese C: The management of pineal tumors as a model for a multidisciplinary approach in neuro-oncology. *Neurochirurgie* 61:208-211, 2015
 196. Frappaz D: Pediatric teratomas: Still fascinating. *Pediatr Blood Cancer* 62:1127-1128, 2015
 197. Gabriel L, Darcissac C, Goutelle S, Seve P, Vial T, de La Gastine B. Lower limb edema during valpromide treatment: case report and literature review. *Rev Med Interne*, 2015; 36(10): 698-700.

198. Gagniere J, Dupre A, Chabaud S, Peyrat P, Meeus P, Rivoire M: Retroperitoneal nodal metastases from colorectal cancer: Curable metastases with radical retroperitoneal lymphadenectomy in selected patients. *Eur J Surg Oncol* 41:731-737, 2015
199. Galmarini CM, Tredan O, Galmarini FC. Survivorship in untreated breast cancer patients. *Med Oncol*, 2015; 32(2): 466.
200. Gao Y, Duran S, Lydon JP, DeMayo FJ, Burghardt RC, Bayless KJ, Bartholin L, Li Q: Constitutive activation of transforming growth factor Beta receptor 1 in the mouse uterus impairs uterine morphology and function. *Biol Reprod* 92:34, 2015
201. Gaspar N, Hawkins DS, Dirksen U, Lewis IJ, Ferrari S, Le Deley MC, Kovar H, Grimer R, Whelan J, Claude L, Delattre O, Paulussen M, Picci P, Sundby HK, van den Berg H, Ladenstein R, Michon J, Hjorth L, Judson I, Luksch R, Bernstein ML, Marec-Berard P, Brennan B, Craft AW, Womer RB, Juergens H, Oberlin O: Ewing Sarcoma: Current Management and Future Approaches Through Collaboration. *J Clin Oncol* 33:3036-3046, 2015
202. Gerfaud-Valentin M, Seve P, Hot A, Broussolle C, Jamilloux Y. Pathophysiology, subtypes, and treatments of adult-onset Still's disease: An update. *Rev Med Interne*, 2015; 36(5): 319-327.
203. Ghesquieres H, Slager SL, Jardin F, Veron AS, Asmann YW, Maurer MJ, Fest T, Habermann TM, Bene MC, Novak AJ, Mareschal S, Haioun C, Lamy T, Ansell SM, Tilly H, Witzig TE, Weiner GJ, Feldman AL, Dogan A, Cunningham JM, Olswold CL, Molina TJ, Link BK, Milpied N, Cox DG, Salles GA, Cerhan JR: Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. *J Clin Oncol* 33:3930-3937, 2015
204. Ghesquieres H: Pneumonitis following immunochemotherapy with rituximab: a new well-designed retrospective study to better assess the risks. *Leuk Lymphoma* 56:1577-1578, 2015
205. Ghirelli C, Reyat F, Jeanmougin M, Zollinger R, Sirven P, Michea P, Caux C, Bendriss-Vermare N, Donnadieu MH, Caly M, Fourchette V, Vincent-Salomon A, Sigal-Zafrani B, Sastre-Garau X, Soumelis V: Breast Cancer Cell-Derived GM-CSF Licenses Regulatory Th2 Induction by Plasmacytoid Predendritic Cells in Aggressive Disease Subtypes. *Cancer Res* 75:2775-2787, 2015
206. Gibert B, Mehlen P: Dependence Receptors and Cancer: Addiction to Trophic Ligands. *Cancer Res* 75:5171-5175, 2015
207. Ginoux E, Julia F, Balme B, Thomas L, Dalle S. T-lymphoblastic lymphoma with cutaneous involvement. *World J Clin Cases*, 2015; 3(8): 727-731.

208. Girard N, Ruffini E, Marx A, Faivre-Finn C, Peters S; ESMO Guidelines Committee. Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2015 Sep;26 Suppl 5:v40-55
209. Goldman-Lévy G, Rigau V, Bléchet C, Bens G, Muckensturm B, Delage M, Labrousse F, Haddad V, Attignon V, Pissaloux D, de la Fouchardière A. Primary melanoma of the leptomeninges with bap1 expression-loss in the setting of a nevus of ota: A clinical, morphological and genetic study of 2 cases. *Brain Pathol*. 2016 Feb 2.
210. Goncalves A, Pierga JY, Ferrero JM, Mouret-Reynier MA, Bachelot T, Delva R, Fabbro M, Lerebours F, Lotz JP, Linassier C, Dohollou N, Eymard JC, Leduc B, Lemonnier J, Martin AL, Boher JM, Viens P, Roche H: UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel-5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer. *Ann Oncol* 26:1692-1697, 2015
211. Goulvent T, Ray-Coquard I, Borel S, Haddad V, Devouassoux-Shisheboran M, Vacher-Lavenu MC, Pujade-Laurraine E, Savina A, Maillet D, Gillet G, Treilleux I, Rimokh R. DICER1 and FOXL2 mutations in ovarian sex cord-stromal tumors: a GINECO Group Study. *Histopathology*. 2015, in press
212. Grados A, Ebbo M, Bernit E, Veit V, Mazodier K, Jean R, Coso D, Aurrans-Schleinitz T, Broussais F, Bouabdallah R, Gravis G, Goncalves A, Giovaninni M, Seve P, Chetaille B, Gavet-Bongo F, Weitten T, Pavic M, Harle JR, Schleinitz N. Sarcoidosis Occurring After Solid Cancer: A Nonfortuitous Association: Report of 12 Cases and Review of the Literature. *Medicine (Baltimore)*, 2015; 94(28): e928.
213. Gruenberger T, Bridgewater J, Chau I, Garcia AP, Rivoire M, Mudan S, Lasserre S, Hermann F, Waterkamp D, Adam R: Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. *Ann Oncol* 26:702-708, 2015
214. Grunewald TG, Bernard V, Gilardi-Hebenstreit P, Raynal V, Surdez D, Aynaud MM, Mirabeau O, Cidre-Aranaz F, Tirode F, Zaidi S, Perot G, Jonker AH, Lucchesi C, Le Deley MC, Oberlin O, Marec-Berard P, Veron AS, Reynaud S, Lapouble E, Boeva V, Rio FT, Alonso J, Bhatia S, Pierron G, Cancel-Tassin G, Cussenot O, Cox DG, Morton LM, Machiela MJ, Chanock SJ, Charnay P, Delattre O: Chimeric EWSR1-FLI1 regulates the Ewing sarcoma susceptibility gene EGR2 via a GGAA microsatellite. *Nat Genet* 47:1073-1078, 2015
215. Guigay J, Fayette J, Dillies AF, Sire C, Kerger JN, Tennevet I, Machiels JP, Zanetta S, Pointreau Y, Bozec Le ML, Henry S, Schilf A, Bourhis J: Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or

- metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study. *Ann Oncol* 26:1941-1947, 2015
216. Guinaudeau F, Beurrier F, Rosay H, Carrabin N, Faure C, Ferraioli D, Chopin N: [Satisfaction in ambulatory patients with breast-conserving surgery and sentinel node biopsy for breast cancer]. *Gynecol Obstet Fertil* 43:213-218, 2015
 217. He J, Xiu L, De Porre P, Dass R, Thomas X. Decitabine reduces transfusion dependence in older patients with acute myeloid leukemia: results from a post hoc analysis of a randomized phase III study. *Leuk Lymphoma*, 2015; 56(4): 1033-1042.
 218. Heiblig M, Bozzoli V, Saison J, Thomas X, De Croze D, Traverse-Glehen A, Cosmidis A, Chidiac C, Ferry T, Alanio A, Bienvenu AL, Dupont D, Ducastelle-Lepretre S, Michallet M, Ader F. Combined medico-surgical strategy for invasive sino-orbito-cerebral breakthrough fungal infection with *Hormoglyphiella aspergillata* in an acute leukaemia patient. *Mycoses*, 2015; 58(5): 308-312.
 219. Heiblig M, Elhamri M, Michallet M, Thomas X. Adoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptors. *World J Stem Cells*, 2015; 7(7): 1022-1038.
 220. Heiblig M, Elhamri M, Nicolini FE, Wattel E, Michallet M, Salles G, Thomas X. Effect of Initial Body Mass Index on Survival Outcome of Patients With Acute Leukemia: A Single-Center Retrospective Study. *Clin Lymphoma Myeloma Leuk*, 2015; 15 Suppl:S7-13.
 221. Hermet E, Cabrespine A, Guieze R, Garnier A, Tempescul A, Lenain P, Bouabdallah R, Vilque JP, Frayfer J, Bordessoule D, Sibon D, Janvier M, Caillot D, Biron P, Legros L, Choufi B, Drenou B, Gorin NC, Bilger K, Tamburini J, Soussain C, Brechignac S, Bay JO: Autologous hematopoietic stem cell transplantation in elderly patients (≥ 70 years) with non-Hodgkin's lymphoma: A French Society of Bone Marrow Transplantation and Cellular Therapy retrospective study. *J Geriatr Oncol* 6:346-352, 2015
 222. Heudel PE, Selle F, Morice P, Rouzier R, Taieb S, Devouassoux-Shisheboran M, Genestie C, Balleyguier C, Ray-Coquard I: [Initial management of advanced ovarian cancer: What radiological, pathological and surgical information are important for optimal therapeutic strategy?]. *Bull Cancer* 102:772-779, 2015
 223. Ho Quoc C, Carrabin N, Meruta A, Piat JM, Delay E, Faure C: [Lipofilling and breast cancer: Literature review in 2015?]. *J Gynecol Obstet Biol Reprod (Paris)* 44:812-817, 2015
 224. Ho Quoc C, Delay E: [How to treat fat necrosis after lipofilling into the breast?]. *Ann Chir Plast Esthet* 60:179-183, 2015

225. Ho Quoc C, Fakiha M, Meruta A, Dlimi C, Piat JM, Delay E: Breast lipofilling: A new treatment of Becker nevus syndrome. *Ann Chir Plast Esthet* 60:336-339, 2015
226. Ho Quoc C, Faure C, Carrabin N, Istasse F, Rivoire M, Delay E: [Glandular posterior flap of the breast for oncoplastic surgery]. *J Gynecol Obstet Biol Reprod (Paris)* 44:510-515, 2015
227. Ho Quoc C, Foyatier JL, Meruta A, Piat JM, Michel G, Delay E: Lipofilling, an efficient solution for breast sequelae after cardiothoracic surgery. *Ann Chir Plast Esthet* 60:522-526, 2015
228. Ho Quoc C, Piat JM, Carrabin N, Meruta A, Faure C, Delay E: Breast reconstruction with fat grafting and BRAVA pre-expansion: Efficacy evaluation in 45 cases. *Ann Chir Plast Esthet* 2015
229. Ho Quoc C, Piat JM, Michel G, Dlimi C, La MS, Delay E: [Fat grafting to improve severe tuberous breast]. *J Gynecol Obstet Biol Reprod (Paris)* 44:503-509, 2015
230. Ho Quoc C, Taupin T, Guerin N, Delay E: Volumetric evaluation of fat resorption after breast lipofilling. *Ann Chir Plast Esthet* 60:495-499, 2015
231. Hollestelle A, van der Baan FH, Berchuck A, Johnatty SE, Aben KK, Agnarsson BA, Aittomaki K, Alducci E, Andrulis IL, Anton-Culver H, Antonenkova NN, Antoniou AC, Apicella C, Arndt V, Arnold N, Arun BK, Arver B, Ashworth A, Baglietto L, Balleine R, Bandera EV, Barrowdale D, Bean YT, Beckmann L, Beckmann MW, Benitez J, Berger A, Berger R, Beuselinck B, Bisogna M, Bjorge L, Blomqvist C, Bogdanova NV, Bojesen A, Bojesen SE, Bolla MK, Bonanni B, Brand JS, Brauch H, Brenner H, Brinton L, Brooks-Wilson A, Bruinsma F, Brunet J, Bruning T, Budzilowska A, Bunker CH, Burwinkel B, Butzow R, Buys SS, Caligo MA, Campbell I, Carter J, Chang-Claude J, Chanock SJ, Claes KB, Collee JM, Cook LS, Couch FJ, Cox A, Cramer D, Cross SS, Cunningham JM, Cybulski C, Czene K, Damiola F, Dansonka-Mieszkowska A, Darabi H, de la Hoya M, deFazio A, Dennis J, Devilee P, Dicks EM, Diez O, Doherty JA, Domchek SM, Dorfling CM, Dork T, Silva ID, du BA, Dumont M, Dunning AM, Duran M, Easton DF, Eccles D, Edwards RP, Ehrencrona H, Ejlertsen B, Ekici AB, Ellis SD, Engel C, Eriksson M, Fasching PA, Feliubadalo L, Figueroa J, Flesch-Janys D, Fletcher O, Fontaine A, Fortuzzi S, Fostira F, Fridley BL, Friebel T, Friedman E, Friel G, Frost D, Garber J, Garcia-Closas M, Gayther SA, Gentry-Maharaj A, Gerdes AM, Giles GG, Glasspool R, Glendon G, Godwin AK, Goodman MT, Gore M, Greene MH, Grip M, Gronwald J, Gschwantler KD, Guenel P, Guzman SR, Haeberle L, Haiman CA, Hall P, Halverson SL, Hamann U, Hansen TV, Harter P, Hartikainen JM, Healey S, Hein A, Heitz F, Henderson BE, Herzog J, MA TH, Hogdall CK, Hogdall E, Hogervorst FB, Hopper JL, Humphreys K, Huzarski T, Imyanitov EN, Isaacs C, Jakubowska A, Janavicius R, Jaworska K, Jensen A, Jensen UB, Johnson N, Jukkola-Vuorinen A, Kabisch M,

- Karlan BY, Kataja V, Kauff N, Kelemen LE, Kerin MJ, Kiemeny LA, Kjaer SK, Knight JA, Knol-Bout JP, Konstantopoulou I, Kosma VM, Krakstad C, Kristensen V, Kuchenbaecker KB, Kupryjanczyk J, Laitman Y, Lambrechts D, Lambrechts S, Larson MC, Lasa A, Laurent-Puig P, Lazaro C, Le ND, Le ML, Leminen A, Lester J, Levine DA, Li J, Liang D, Lindblom A, Lindor N, Lissowska J, Long J, Lu KH, Lubinski J, Lundvall L, Lurie G, Mai PL, Mannermaa A, Margolin S, Mariette F, Marme F, Martens JW, Massuger LF, Maugard C, Mazoyer S, McGuffog L, McGuire V, McLean C, McNeish I, Meindl A, Menegaux F, Menendez P, Menkiszak J, Menon U, Mensenkamp AR, Miller N, Milne RL, Modugno F, Montagna M, Moysich KB, Muller H, Mulligan AM, Muranen TA, Narod SA, Nathanson KL, Ness RB, Neuhausen SL, Nevanlinna H, Neven P, Nielsen FC, Nielsen SF, Nordestgaard BG, Nussbaum RL, Odunsi K, Offit K, Olah E, Olopade OI, Olson JE, Olson SH, Oosterwijk JC, Orlow I, Orr N, Orsulic S, Osorio A, Ottini L, Paul J, Pearce CL, Pedersen IS, Peissel B, Pejovic T, Pelttari LM, Perkins J, Permut-Wey J, Peterlongo P, Peto J, Phelan CM, Phillips KA, Piedmonte M, Pike MC, Platte R, Plisiecka-Halasa J, Poole EM: No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. *Gynecol Oncol* 2015
232. Honore C, Meeus P, Stoeckle E, Bonvalot S: Soft tissue sarcoma in France in 2015: Epidemiology, classification and organization of clinical care. *J Visc Surg* 152:223-230, 2015
233. Houang M, Castillo C, La Marca S, Combemale P, Wang Q, Paindavoine S, Pissaloux D, de la Fouchardiere A. An unusual case of desmoplastic melanoma containing an osteoclast-like giant cell-rich nodule. *Am J Dermatopathol*. 2015 Apr;37(4):299-30
234. Houede N, Beuzeboc P, Gourgou S, Tosi D, Moise L, Gravis G, Delva R, Flechon A, Latorzeff I, Ferrero JM, Oudard S, Tartas S, Laguerre B, Topart D, Roubaud G, Agherbi H, Rebillard X, Azria D: Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France. *BMC Cancer* 15:222, 2015
235. Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, Wolf J, Raje NS, Diamond EL, Hollebecque A, Gervais R, Elez-Fernandez ME, Italiano A, Hofheinz RD, Hidalgo M, Chan E, Schuler M, Lasserre SF, Makrutzki M, Sirzen F, Veronese ML, Tabernero J, Baselga J: Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. *N Engl J Med* 373:726-736, 2015
236. Integrin $\alpha\beta 8$ -Mediated TGF- β Activation by Effector Regulatory T Cells Is Essential for Suppression of T-Cell-Mediated Inflammation. Worthington JJ, Kelly A, Smedley C, Bauché D, Campbell S, Marie JC, Travis MA. *Immunity*. 2015 May 19;42(5):903-15.

237. Ivanov AV, Smirnova OA, Petrushanko IY, Ivanova ON, Karpenko IL, Alekseeva E, Sominskaya I, Makarov AA, Bartosch B, Kochetkov SN, Isagulians MG. HCV core protein uses multiple mechanisms to induce oxidative stress in human hepatoma huh7 cells. *Viruses*. 2015 May 29;7(6):2745-70.
238. Jamilloux I, Valeyre D, Lortholary O, Bernard C, Kerever S, Lelievre L, Neel A, Broussolle C, Seve P. The spectrum of opportunistic diseases complicating sarcoidosis. *Autoimmun Rev*, 2015; 14(1): 64-74.
239. Jamilloux Y, Gerfaud-Valentin M, Henry T, Seve P. Treatment of adult-onset Still's disease: a review. *Ther Clin Risk Manag*, 2015; 11:33-43.
240. Jamilloux Y, Gerfaud-Valentin M, Martinon F, Belot A, Henry T, Seve P. Pathogenesis of adult-onset Still's disease: new insights from the juvenile counterpart. *Immunol Res*, 2015; 61(1-2): 53-62.
241. Jamilloux Y, Sarabi M, Kerever S, Bousely N, le SA, Valgueblasse V, Carrier P, Loustaud-Ratti V, Sautereau D, Fauchais AL, Francois B, Vidal E: Adherence to online monitoring of patient-reported outcomes by patients with chronic inflammatory diseases: a feasibility study. *Lupus* 24:1429-1436, 2015
242. Jauffret C, Houvenaeghel G, Classe JM, Garbay JR, Giard S, Charitansky H, Cohen M, Belichard C, Faure C, Darai E, Hudry D, Azuar P, Villet R, Gimbergues P, Tunon de LC, Martino M, Coutant C, Dravet F, Chauvet MP, Chereau EE, Penault-Llorca F, Goncalves A, Lambaudie E: [Lobular invasive breast cancer prognostic factors: About 940 patients]. *Gynecol Obstet Fertil* 43:712-717, 2015
243. Jenkins MA, Dowty JG, Ait OD, Mathews JD, Hopper JL, Drouet Y, Lasset C, Bonadona V, Win AK: Short-term risk of colorectal cancer in individuals with lynch syndrome: a meta-analysis. *J Clin Oncol* 33:326-331, 2015
244. Jerusalem G, Bachelot T, Barrios C, Neven P, Di LA, Janni W, de BR: A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer. *Cancer Treat Rev* 41:94-104, 2015
245. Jiang X, Pissaloux D, de la Fouchardiere C, Desseigne F, Wang Q, Attignon V, Fondrevelle ME, De La Fouchardiere A, Perol M, Cassier P, Seigne C, Perol D, Ray-Coquard I, Meeus P, Fayette J, Flechon A, Le CA, Penel N, Tredan O, Blay JY: The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: Characterization, validation, and prognostic value. *Oncotarget* 6:26388-26399, 2015
246. Jobard E, Blanc E, Negrier S, Escudier B, Gravis G, Chevreau C, Elena-Herrmann B, Tredan O: A serum metabolomic fingerprint of bevacizumab and temsirolimus combination as first-line treatment of metastatic renal cell carcinoma. *Br J Cancer* 113:1148-1157, 2015

247. Jobard E, Blanc E, Negrier S, Escudier B, Gravis G, Chevreau C, Elena-Herrmann B, Tredan O. A serum metabolomic fingerprint of bevacizumab and temsirolimus combination as first-line treatment of metastatic renal cell carcinoma. *Br J Cancer*, 2015; 113(8): 1148-1157.
248. Jönsson L, Justo N, Musayev A, Krishna A, Burke T, Pellissier J, Judson I, Staddon A, Blay JY. Cost of treatment in patients with metastatic soft tissue sarcoma who respond favourably to chemotherapy. The SARcoma treatment and Burden of Illness in North America and Europe (SABINE) study. *Eur J Cancer Care (Engl)*. 2015 Apr 28.
249. Jordheim LP, Puy JY, Cros-Perrial E, Peyrottes S, Lefebvre I, Perigaud C, Dumontet C. Determination of the enzymatic activity of cytosolic 5'-nucleotidase cN-II in cancer cells: development of a simple analytical method and related cell line models. *Anal Bioanal Chem*, 2015; 407(19): 5747-5758.
250. Jordheim LP, Ribrag V, Ghesquieres H, Pallardy S, Delarue R, Tilly H, Haioun C, Jardin F, Demangel D, Salles GA, Dumontet C: Single nucleotide polymorphisms in ABCB1 and CBR1 can predict toxicity to R-CHOP type regimens in patients with diffuse non-Hodgkin lymphoma. *Haematologica* 100:e204-e206, 2015
251. Jouary T, Kubica E, Dalle S, Pages C, Duval-Modeste AB, Guillot B, Mansard S, Saiag P, Aubin F, Bedane C, Dalac S, Domp Martin A, Granel-Brocard F, Lok C, Stoebner PE, Lacour JP, Leccia MT, Diallo A, Ezzedine K, Mateus C. Sentinel node status and immunosuppression: recurrence factors in localized Merkel cell carcinoma. *Acta Derm Venereol*, 2015; 95(7): 835-840.
252. Julian-Reynier C, Resseguier N, Bouhnik AD, Eisinger F, Lasset C, Fourme E, Nogues C: Cigarette smoking in women after BRCA1/2 genetic test disclosure: a 5-year follow-up study of the GENEPSO PS cohort. *Genet Med* 17:117-124, 2015
253. Kadia TM, Thomas XG, Dmoszynska A, Wierzbowska A, Minden M, Arthur C, Delaunay J, Ravandi F, Kantarjian H. Decitabine improves outcomes in older patients with acute myeloid leukemia and higher blast counts. *Am J Hematol*, 2015; 90(7): E139-141.
254. Kasenda B, Ferreri AJ, Marturano E, Forst D, Bromberg J, Ghesquieres H, Ferlay C, Blay JY, Hoang-Xuan K, Pulczynski EJ, Fossa A, Okoshi Y, Chiba S, Fritsch K, Omuro A, O'Neill BP, Bairey O, Schandelmaier S, Gloy V, Bhatnagar N, Haug S, Rahner S, Batchelor TT, Illerhaus G, Briel M: First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysis. *Ann Oncol* 26:1305-1313, 2015

255. Kassem L, Deygas M, Fattet L, Lopez J, Goulvent T, Lavergne E, Chabaud S, Carrabin N, Chopin N, Bachelot T, Gillet G, Treilleux I, Rimokh R: TIF1gamma interferes with TGFbeta1/SMAD4 signaling to promote poor outcome in operable breast cancer patients. *BMC Cancer* 15:453, 2015
256. Kassem L, Deygas M, Fattet L, Lopez J, Goulvent T, Lavergne E, Chabaud S, Carrabin N, Chopin N, Bachelot T, Gillet G, Treilleux I, Rimokh R. TIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patients, *BMC Cancer*, 2015, in press
257. Khalifa J, Ouali M, Chaltiel L, Le GS, Le CA, Blay JY, Cousin P, Chaigneau L, Bompas E, Piperno-Neumann S, Bui-Nguyen B, Rios M, Delord JP, Penel N, Chevreau C: Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group. *BMC Cancer* 15:700, 2015
258. Kloke M, Cherny N; ESMO Guidelines Committee. Treatment of dyspnoea in advanced cancer patients: ESMO Clinical Practice Guidelines. *Ann Oncol.* 2015 Sep;26 Suppl 5:v169-73
259. Klysz D, Tai X, Robert PA, Craveiro M, Cretenet G, Oburoglu L, Mongellaz C, Floess S, Fritz V, Matias MI, Yong C, Surh N, Marie JC, Huehn J, Zimmermann V, Kinet S, Dardalhon V, Taylor N. Glutamine-dependent α -ketoglutarate production regulates the balance between T helper 1 cell and regulatory T cell generation. *Sci Signal.* 2015 Sep 29;8(396):ra97.
260. Kramar A, Negrier S, Sylvester R, Joniau S, Mulders P, Powles T, Bex A, Bonnetain F, Bossi A, Bracarda S, Bukowski R, Catto J, Choueiri TK, Crabb S, Eisen T, El DM, Fitzpatrick J, Flamand V, Goebell PJ, Gravis G, Houede N, Jacqmin D, Kaplan R, Malavaud B, Massard C, Melichar B, Mourey L, Nathan P, Pasquier D, Porta C, Pouessel D, Quinn D, Ravaud A, Rolland F, Schmidinger M, Tombal B, Tosi D, Vauleon E, Volpe A, Wolter P, Escudier B, Filleron T: Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project. *Ann Oncol* 26:2392-2398, 2015
261. Kuchenbaecker KB, Ramus SJ, Tyrer J, Lee A, Shen HC, Beesley J, Lawrenson K, McGuffog L, Healey S, Lee JM, Spindler TJ, Lin YG, Pejovic T, Bean Y, Li Q, Coetzee S, Hazelett D, Miron A, Southey M, Terry MB, Goldgar DE, Buys SS, Janavicius R, Dorfling CM, van Rensburg EJ, Neuhausen SL, Ding YC, Hansen TV, Jonson L, Gerdes AM, Ejlertsen B, Barrowdale D, Dennis J, Benitez J, Osorio A, Garcia MJ, Komenaka I, Weitzel JN, Ganschow P, Peterlongo P, Bernard L, Viel A, Bonanni B, Peissel B, Manoukian S, Radice P, Papi L, Ottini L, Fostira F, Konstantopoulou I, Garber J, Frost D, Perkins J, Platte R, Ellis S, Godwin AK, Schmutzler RK, Meindl A, Engel C, Sutter C, Sinilnikova OM, Damiola F, Mazoyer S, Stoppa-Lyonnet D, Claes K, De LK, Kirk J, Rodriguez GC, Piedmonte M, O'Malley DM, de la Hoya M, Caldes T, Aittomaki K,

- Nevanlinna H, Collee JM, Rookus MA, Oosterwijk JC, Tihomirova L, Tung N, Hamann U, Isacacs C, Tischkowitz M, Imyanitov EN, Caligo MA, Campbell IG, Hogervorst FB, Olah E, Diez O, Blanco I, Brunet J, Lazaro C, Pujana MA, Jakubowska A, Gronwald J, Lubinski J, Sukiennicki G, Barkardottir RB, Plante M, Simard J, Soucy P, Montagna M, Tognazzo S, Teixeira MR, Pankratz VS, Wang X, Lindor N, Szabo CI, Kauff N, Vijai J, Aghajanian CA, Pfeiler G, Berger A, Singer CF, Tea MK, Phelan CM, Greene MH, Mai PL, Rennert G, Mulligan AM, Tchatchou S, Andrulis IL, Glendon G, Toland AE, Jensen UB, Kruse TA, Thomassen M, Bojesen A, Zidan J, Friedman E, Laitman Y, Soller M, Liljegren A, Arver B, Einbeigi Z, Stenmark-Askmal M, Olopade OI, Nussbaum RL, Rebbeck TR, Nathanson KL, Domchek SM, Lu KH, Karlan BY, Walsh C, Lester J, Hein A, Ekici AB, Beckmann MW, Fasching PA, Lambrechts D, Van NE, Vergote I, Lambrechts S, Dicks E, Doherty JA, Wicklund KG, Rossing MA, Rudolph A, Chang-Claude J, Wang-Gohrke S, Eilber U, Moysich KB, Odunsi K, Sucheston L, Lele S, Wilkens LR, Goodman MT, Thompson PJ, Shvetsov YB, Runnebaum IB, Durst M, Hillemanns P, Dork T, Antonenkova N, Bogdanova N, Leminen A, Pelttari LM, Butzow R, Modugno F, Kelley JL, Edwards RP, Ness RB, du BA, Heitz F, Schwaab I, Harter P, Matsuo K, Hosono S, Orsulic S, Jensen A, Kjaer SK, Hogdall E, Hasmad HN, Azmi MA, Teo SH, Woo YL, Fridley BL, Goode EL, Cunningham JM, Vierkant RA, Bruinsma F, Giles GG, Liang D, Hildebrandt MA, Wu X, Levine DA, Bisogna M, Berchuck A, Iversen ES, Schildkraut JM, Concannon P, Weber RP, Cramer DW, Terry KL, Poole EM, Tworoger SS, Bandera EV, Orlow I, Olson SH, Krakstad C, Salvesen HB, Tangen IL, Bjorge L, van Altena AM, Aben KK, Kiemeny LA, Massuger LF, Kellar M, Brooks-Wilson A, Kelemen LE, Cook LS, Le ND, Cybulski C, Yang H, Lissowska J, Brinton LA, Wentzensen N, Hogdall C, Lundvall L, Nedergaard L, Baker H, Song H, Eccles D, McNeish I, Paul J, Carty K, Siddiqui N, Glasspool R, Whittemore AS, Rothstein JH, McGuire V, Sieh W, Ji BT, Zheng W, Shu XO, Gao YT: Identification of six new susceptibility loci for invasive epithelial ovarian cancer. *Nat Genet* 47:164-171, 2015
262. Lacoste C, Avril MF, Frassati-Biaggi A, Dupin N, Chrétien-Marquet B, Mahé E, Bodemer C, Vergier B, de la Fouchardière A, Fraitag S. Malignant Melanoma Arising in Patients with a Large Congenital Melanocytic Naevus: Retrospective Study of 10 Cases with Cytogenetic Analysis. *Acta Derm Venereol*. 2015 Jun 24;95(6):686-90.
263. Lambert MP, Ancy PB, Esposti DD, Cros MP, Sklias A, Scoazec JY, Durantel D, Hernandez-Vargas H, Herceg Z. Aberrant DNA methylation of imprinted loci in hepatocellular carcinoma and after in vitro exposure to common risk factors. *Clin Epigenetics*. 2015 Feb 27;7(1):15.
264. Laprie A, Hu Y, Alapetite C, Carrie C, Habrand JL, Bolle S, Bondiau PY, Ducassou A, Huchet A, Bertozzi AI, Perel Y, Moyal E, Balosso J: Paediatric brain tumours: A review of radiotherapy, state of the art and challenges for the future regarding protontherapy and carbontherapy. *Cancer Radiother* 19:775-789, 2015

265. Laustriat D, Gide J, Barrault L, Chautard E, Benoit C, Auboeuf D, Boland A, Battail C, Artiguenave F, Deleuze JF, Benit P, Rustin P, Franc S, Charpentier G, Furling D, Bassez G, Nissan X, Martinat C, Peschanski M, Baghdoyan S: In Vitro and In Vivo Modulation of Alternative Splicing by the Biguanide Metformin. *Mol Ther Nucleic Acids* 4:e262, 2015
266. Lavoine N, Colas C, Muleris M, Bodo S, Duval A, Entz-Werle N, Coulet F, Cabaret O, Andreiuolo F, Charpy C, Sebillé G, Wang Q, Lejeune S, Buisine MP, Leroux D, Couillaud G, Leverger G, Fricker JP, Guimbaud R, Mathieu-Dramard M, Jedraszak G, Cohen-Hagenauer O, Guerrini-Rousseau L, Bourdeaut F, Grill J, Caron O, Baert-Dusermont S, Tinat J, Bougeard G, Frebourg T, Brugieres L: Constitutional mismatch repair deficiency syndrome: clinical description in a French cohort. *J Med Genet* 52:770-778, 2015
267. Lavrut PM, Le Loarer F, Normand C, Grosos C, Dubois R, Buenerd A, Conter C, Dijoud F, Blay JY, Collardeau-Frachon S. Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Report of a Bilateral Case in a Teenager Associated with SMARCA4 Germline Mutation. *Pediatr Dev Pathol.* 2016 Jan-Feb;19(1):56-60
268. Lazar V, Rubin E, Depil S, Pawitan Y, Martini JF, Gomez-Navarro J, Yver A, Kan Z, Dry JR, Kehren J, Validire P, Rodon J, Vielh P, Ducreux M, Galbraith S, Lehnert M, Onn A, Berger R, Pierotti MA, Porgador A, Pramesh CS, Ye DW, Carvalho AL, Batist G, Le CT, Morice P, Besse B, Vassal G, Mortlock A, Hansson J, Berindan-Neagoe I, Dann R, Haspel J, Irimie A, Laderman S, Nechushtan H, Al Omari AS, Haywood T, Bresson C, Soo KC, Osman I, Mata H, Lee JJ, Jhaveri K, Meurice G, Palmer G, Lacroix L, Koscielny S, Eterovic KA, Blay JY, Buller R, Eggermont A, Schilsky RL, Mendelsohn J, Soria JC, Rothenberg M, Scoazec JY, Hong WK, Kurzrock R: A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer. *Oncotarget* 6:14139-14152, 2015
269. Lazarovici J, Dartigues P, Brice P, Oberic L, Gaillard I, Hunault-Berger M, Broussais-Guillaumot F, Gyan E, Bologna S, Nicolas-Virelizier E, Touati M, Casasnovas O, Delarue R, Orsini-Piocelle F, Stamatoullas A, Gabarre J, Fornecker LM, Gastinne T, Peyrade F, Roland V, Bachy E, Andre M, Mounier N, Ferme C: Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study. *Haematologica* 100:1579-1586, 2015
270. Le Cesne A, Ray-Coquard I, Duffaud F, Chevreau C, Penel N, Bui NB, Piperno-Neumann S, Delcambre C, Rios M, Chaigneau L, Le MC, Guillemet C, Bertucci F, Bompas E, Linassier C, Olivier T, Kurtz JE, Even C, Cousin P, Yves BJ: Trabectedin in patients with advanced soft tissue sarcoma: a retrospective national analysis of the French Sarcoma Group. *Eur J Cancer* 51:742-750, 2015
271. Le Cesne A, Blay JY, Domont J, Tresch-Bruneel E, Chevreau C, Bertucci F, Delcambre C, Saada-Bouzid E, Piperno-Neumann S, Bay JO, Mir O, Ray-Coquard I, Ryckewaert T, Valentin T, Isambert N, Italiano A, Clisant S, Penel N:

- Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial. *Lancet Oncol* 16:312-319, 2015
272. Le Cornet C, Fervers B, Dalton SO, Feychting M, Pukkala E, Tynes T, Hansen J, Nordby KC, Beranger R, Kauppinen T, Uuksulainen S, Wiebert P, Woldbaek T, Skakkebaek NE, Olsson A, Schuz J: Testicular germ cell tumours and parental occupational exposure to pesticides: a register-based case-control study in the Nordic countries (NORD-TEST study). *Occup Environ Med* 72:805-811, 2015
273. Le Guen R, Madelaine I, Tournamille JF, Bellanger A, Astier A, Braguer D, Ollivier C, Bardin C, Lemare F, Daouphars M, Pinguet F, Latour JF, Vigneron J, Tilleul P: [Study impact: Descriptive analysis of pharmacist's clinical practice in onco-hematology]. *Ann Pharm Fr* 73:223-228, 2015
274. Le Jeune C, Thomas X. Antibody-based therapies in B-cell lineage acute lymphoblastic leukaemia. *Eur J Haematol*, 2015; 94(2): 99-108.
275. Le Loarer F, Watson S, Pierron G, de Montpreville VT, Ballet S, Firmin N, Auguste A, Pissaloux D, Boyault S, Paindavoine S, Dechelotte PJ, Besse B, Vignaud JM, Brevet M, Fadel E, Richer W, Treilleux I, Masliah-Planchon J, Devouassoux-Shisheboran M, Zalcman G, Allory Y, Bourdeaut F, Thivolet-Bejui F, Ranchere-Vince D, Girard N, Lantuejoul S, Galateau-Salle F, Coindre JM, Leary A, Delattre O, Blay JY, Tirode F: SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas. *Nat Genet* 47:1200-1205, 2015
276. Le Tourneau C, Delord JP, Goncalves A, Gavaille C, Dubot C, Isambert N, Campone M, Tredan O, Massiani MA, Mauborgne C, Armanet S, Servant N, Bieche I, Bernard V, Gentien D, Jezequel P, Attignon V, Boyault S, Vincent-Salomon A, Servois V, Sablin MP, Kamal M, Paoletti X: Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. *Lancet Oncol* 16:1324-1334, 2015
277. Lecarpentier J, Nogues C, Mouret-Fourme E, Buecher B, Gauthier-Villars M, Stoppa-Lyonnet D, Bonadona V, Fricker JP, Berthet P, Caron O, Coupier I, Pujol P, Faivre L, Gesta P, Eisinger F, Mari V, Gladieff L, Lortholary A, Luporsi E, Leroux D, Venat-Bouvet L, Maugard CM, Colas C, Tinat J, Lasset C, Andrieu N: Breast Cancer Risk Associated with Estrogen Exposure and Truncating Mutation Location in BRCA1/2 Carriers. *Cancer Epidemiol Biomarkers Prev* 24:698-707, 2015
278. Lecler A, Lenoir M, Peron J, Denoyelle F, Garabedian EN, Pointe HD, Nevoux J: Magnetic resonance imaging at one year for detection of postoperative residual cholesteatoma in children: Is it too early? *Int J Pediatr Otorhinolaryngol* 79:1268-1274, 2015

279. Legroux L, Rousset P, Marec-Berard P, Garnier N, Rousset-Jablonski C: [Ovarian insufficiency diagnosis in a context of hypogonadotropic hypogonadism]. *Gynecol Obstet Fertil* 43:623-625, 2015
280. Lerebours F, Saltel P, Bethune-Volters A, Nallet G, Bourdat P, Vesin-Etterlen F, Zernik N, Flinois A: [Satisfaction of Breast Cancer patients treated by chemotherapy outpatient clinics: Results of the TemporELLES survey]. *Bull Cancer* 102:316-323, 2015
281. Lesne A, Foray N, Cathala G, Forné T, Wong H, Victor JM. Chromatin fiber allostery and the epigenetic code. *J Phys Condens Matter*. 2015 Feb 18;27(6):064114
282. Lesort C, Debarbieux S, Duru G, Dalle S, Poulhalon N, Thomas L. Dermoscopic Features of Onychomatricoma: A Study of 34 Cases. *Dermatology*, 2015; 231(2): 177-183.
283. Levy A, Azria D, Pignon JP, Delarochefordiere A, Martel-Lafay I, Rio E, Malka D, Conroy T, Miglianico L, Becouarn Y, Malekzadeh K, Leclercq J, Juzyna B, Ezra P, Lemanski C, Deutsch E: Low response rate after cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: long-term results of the UNICANCER ACCORD 16 phase II trial. *Radiother Oncol* 114:415-416, 2015
284. Levy C, Allouache D, Lacroix J, Dugue AE, Supiot S, Campone M, Mahe M, Kichou S, Leheurteur M, Hanzen C, Dieras V, Kirova Y, Campana F, Le RE, Gras L, Bachelot T, Sunyach MP, Hrab I, Geffrelot J, Gunzer K, Constans JM, Grellard JM, Clarisse B, Paoletti X: REBECA: a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumours. *Ann Oncol* 26:2359, 2015
285. Li F, Su Y, Cheng Y, Jiang X, Peng Y, Li Y, Lu J, Gu Y, Zhang C, Cao Y, Wang W, Ning G: Conditional deletion of Men1 in the pancreatic beta-cell leads to glucagon-expressing tumor development. *Endocrinology* 156:48-57, 2015
286. Luangsay S, Ait-Goughoulte M, Michelet M, Floriot O, Bonnin M, Gruffaz M, Rivoire M, Fletcher S, Javanbakht H, Lucifora J, Zoulim F, Durantel D: Expression and functionality of Toll- and RIG-like receptors in HepaRG cells. *J Hepatol* 63:1077-1085, 2015
287. Luangsay S, Gruffaz M, Isorce N, Testoni B, Michelet M, Faure-Dupuy S, Maadadi S, Ait-Goughoulte M, Parent R, Rivoire M, Javanbakht H, Lucifora J, Durantel D, Zoulim F: Early inhibition of hepatocyte innate responses by hepatitis B virus. *J Hepatol* 63:1314-1322, 2015
288. Machiels JP, Haddad RI, Fayette J, Licitra LF, Tahara M, Vermorken JB, Clement PM, Gauler T, Cupissol D, Grau JJ, Guigay J, Caponigro F, de CG, Jr., de S, V, Keilholz U, Del Campo JM, Cong XJ, Ehrnrooth E, Cohen EE: Afatinib

- versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial. *Lancet Oncol* 16:583-594, 2015
289. Machon C, Bordes C, Cros-Perrial E, Clement Y, Jordheim LP, Lanteri P, Guitton J. Use of designed experiments for the improvement of pre-analytical workflow for the quantification of intracellular nucleotides in cultured cell lines. *J Chromatogr A*, 2015; 1405(116-125).
 290. Maillard S, Damiola F, Clero E, Pertesi M, Robinot N, Rachedi F, Boissin JL, Sebbag J, Shan L, Bost-Bezeaud F, Petitdidier P, Doyon F, Xhaard C, Rubino C, Blanche H, Drozdovitch V, Lesueur F, De VF: Common variants at 9q22.33, 14q13.3, and ATM loci, and risk of differentiated thyroid cancer in the French Polynesian population. *PLoS One* 10:e0123700, 2015
 291. Maillet D, Blay JY, You B, Rachdi A, Gan HK, Péron J. The reporting of adverse events in oncology phase III trials: a comparison of the current status versus the expectations of the EORTC members. *Ann Oncol*. 2016 Jan;27(1):192-8
 292. Maillet D, Gan HK, Blay JY, You B, Péron J. Aggregated adverse-events outcomes in oncology phase III reports: A systematic review. *Eur J Cancer*. 2016 Jan;52:26-32.
 293. Maki RG, Blay JY, Demetri GD, Fletcher JA, Joensuu H, Martin-Broto J, Nishida T, Reichardt P, Schoffski P, Trent JC: Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert Discussion. *Oncologist* 20:823-830, 2015
 294. Mancini J, Le CE, Bouhnik AD, Resseguier N, Lasset C, Mouret-Fourme E, Nogues C, Julian-Reynier C: Disclosure of research results: a randomized study on GENEPSO-PS cohort participants. *Health Expect* 2015
 295. Marabelle A, Filatenkov A, Sagiv-Barfi I, Kohrt H: Radiotherapy and toll-like receptor agonists. *Semin Radiat Oncol* 25:34-39, 2015
 296. Marabelle A, Gray J: Tumor-targeted and immune-targeted monoclonal antibodies: Going from passive to active immunotherapy. *Pediatr Blood Cancer* 62:1317-1325, 2015
 297. Marcel V, Catez F, Diaz JJ: p53, a translational regulator: contribution to its tumour-suppressor activity. *Oncogene* 34:5513-5523, 2015
 298. Marchalot J, Chateaux JF, Faivre M, Mertani HC, Ferrigno R, Deman AL: Dielectrophoretic capture of low abundance cell population using thick electrodes. *Biomicrofluidics* 9:054104, 2015

299. Marec-Berard P, Gomez F, Combet S, Thibault P, Moine PL, Bergeron C: HEDEN Pain Scale: A Shortened Behavioral Scale for Assessment of Prolonged Cancer or Postsurgical Pain in Children Aged 2 to 6 Years. *Pediatr Hematol Oncol* 32:291-303, 2015
300. Marton Z, Guillon R, Krimm I, Preeti, Rahimova R, Egron D, Jordheim LP, Aghajari N, Dumontet C, Perigaud C, Lionne C, Peyrottes S, Chaloin L: Identification of Noncompetitive Inhibitors of Cytosolic 5'-Nucleotidase II Using a Fragment-Based Approach. *J Med Chem* 58:9680-9696, 2015
301. Massard C, Bay JO, Andre T, Blay JY, Goncalves A, Orbach D, Wislez M, Thariat J, Magne N, Vignot S: [Major advances in oncology in 2014: the editorial board of the Bulletin du Cancer point of view]. *Bull Cancer* 102:92-104, 2015
302. Mathieu AL, Verronese E, Rice GI, Fouyssac F, Bertrand Y, Picard C, Chansel M, Walter JE, Notarangelo LD, Butte MJ, Nadeau KC, Csomos K, Chen DJ, Chen K, Delgado A, Rigal C, Bardin C, Schuetz C, Moshous D, Reumaux H, Plenat F, Phan A, Zobot MT, Balme B, Viel S, Bienvenu J, Cochat P, van der Burg M, Caux C, Kemp EH, Rouvet I, Malcus C, Meritet JF, Lim A, Crow YJ, Fabien N, Menetrier-Caux C, De Villartay JP, Walzer T, Belot A: PRKDC mutations associated with immunodeficiency, granuloma, and autoimmune regulator-dependent autoimmunity. *J Allergy Clin Immunol* 135:1578-1588, 2015
303. Meyer V, Flechon A, Tartas S, Fassi-Fehri H, Ruffion A, Martin X, Colombel M: [Impact of neoadjuvant chemotherapy on therapeutic management of muscle-invasive bladder cancer]. *Prog Urol* 25:83-89, 2015
304. Michallet M, Sobh M, Serrier C, Morisset S, Labussiere H, Ducastelle S, Barraco F, Gilis L, Thomas X, Nicolini FE. Allogeneic hematopoietic stem cell transplant for hematological malignancies from mismatched 9/10 human leukocyte antigen unrelated donors: comparison with transplants from 10/10 unrelated donors and human leukocyte antigen identical siblings. *Leuk Lymphoma*, 2015; 56(4): 999-1003.
305. Michel G, Ho QC, Assaf N, Delay E, Sinna R: [Dynamic reconstruction of Achilles tendon by free composite perforator flap with functional assessment]. *Ann Chir Plast Esthet* 60:78-83, 2015
306. Mint Mohamed A, Balsat M, Thenoz M, Koering C, Payen-Gay L, Cheok M, Mortada H, Auboeuf D, Pinatel C, El-Hamri M, Dumontet C, Cros E, Pascale Flandrin-Gresta, Nibourel O, Preudhomme C, Michallet M, Thomas X, Nicolini F, Solly F, Guyotat D, Campos L, Wattel E, Mortreux F. Oncogene- and drug resistance-associated alternative exon usage in acute myeloid leukemia (AML). *Oncotarget*. 2015 May 12.
307. Moreno C, Hezode C, Marcellin P, Bourgeois S, Francque S, Samuel D, Zoulim F, Grange JD, Shukla U, Lenz O, Ouwerkerk-Mahadevan S, Fevery B, Peeters M, Beumont M, Jessner W. Efficacy and safety of simeprevir with PegIFN/ribavirin

- in naïve or experienced patients infected with chronic HCV genotype 4. *J Hepatol.* 2015 May;62(5):1047-55.
308. Morère JF, Viguier J, Touboul C, Pivot X, Blay JY, Coscas Y, Lhomel C, Eisinger F. Lung cancer risks, beliefs and healthcare access among the underprivileged. *Eur J Cancer Prev.* 2015 Jun;24 Suppl:S82-6
 309. Moro-Sibilot L, This S, Blanc P, Sanlaville A, Sisirak V, Bardel E, Boschetti G, Bendriss-Vermare N, Defrance T, Dubois B, Kaiserlian D. Plasmacytoid dendritic cells are dispensable for noninfectious intestinal IgA responses in vivo. *Eur J Immunol.* 2016 Feb;46(2):354-9
 310. Mottolèse C, Szathmari A, Beuriat PA, Frappaz D, Jouvét A, Hermier M: Tectal plate tumours. Our experience with a paediatric surgical series. *Neurochirurgie* 61:193-200, 2015
 311. Mourgues L, Imbert V, Nebout M, Colosetti P, Neffati Z, Lagadec P, Verhoeyen E, Peng C, Duprez E, Legros L, Rochet N, Maguer-Satta V, Nicolini FE, Mary D, Peyron JF. The BMI1 polycomb protein represses cyclin G2-induced autophagy to support proliferation in chronic myeloid leukemia cells. *Leukemia.* 2015 Apr 30
 312. Müssnich P, Raverot G, Jaffrain-Rea ML, Fraggetta F, Wierinckx A, Trouillas J, Fusco A, D'Angelo D. Downregulation of miR-410 targeting the cyclin B1 gene plays a role in pituitary gonadotroph tumors. *Cell Cycle.* 2015;14(16):2590-7
 313. Napoleon B, Lemaistre AI, Pujol B, Caillol F, Lucidarme D, Bourdariat R, Morellon-Mialhe B, Fumex F, Lefort C, Lepilliez V, Palazzo L, Monges G, Poizat F, Giovannini M: In vivo characterization of pancreatic cystic lesions by needle-based confocal laser endomicroscopy (nCLE): proposition of a comprehensive nCLE classification confirmed by an external retrospective evaluation. *Surg Endosc* 2015
 314. Napoleon B, Lemaistre AI, Pujol B, Caillol F, Lucidarme D, Bourdariat R, Morellon-Mialhe B, Fumex F, Lefort C, Lepilliez V, Palazzo L, Monges G, Filoche B, Giovannini M: A novel approach to the diagnosis of pancreatic serous cystadenoma: needle-based confocal laser endomicroscopy. *Endoscopy* 47:26-32, 2015
 315. Navarro R, Tanguy R, Terrier JE, Golfier F, Ruffion A, Paparel P: [Does laparoscopic nephrectomy with vaginal extraction affect the sexual quality of life of patients?]. *Prog Urol* 25:1153-1159, 2015
 316. Nicolas-Virelizier E, Segura-Ferlay C, Ghesquieres H, Chassagne-Clement C, Gargi T, Biron P, Belhabri A, Rey P, Faurie P, Chabaud S, Sebban C: Impact of the introduction of rituximab in first-line follicular lymphoma: a retrospective

- study of 247 unselected patients referred to a single institution with a long-term follow-up. *Hematol Oncol* 33:1-8, 2015
317. Nicolini FE, Etienne G, Dubruille V, Roy L, Huguet F, Legros L, Giraudier S, Coiteux V, Guerci-Bresler A, Lenain P, Cony-Makhoul P, Gardembas M, Hermet E, Rousselot P, Ame S, Gagnieu MC, Pivot C, Hayette S, Maguer-Satta V, Etienne M, Dulucq S, Rea D, Mahon FX: Nilotinib and peginterferon alfa-2a for newly diagnosed chronic-phase chronic myeloid leukaemia (NiloPeg): a multicentre, non-randomised, open-label phase 2 study. *Lancet Haematol* 2:e37-e46, 2015
 318. Nishida T, Blay JY, Hirota S, Kitagawa Y, Kang YK. The standard diagnosis, treatment, and follow-up of gastrointestinal stromal tumors based on guidelines. *Gastric Cancer*. 2016 Jan;19(1):3-14
 319. Nishida T, Tsujimoto M, Takahashi T, Hirota S, Blay JY, Wataya-Kaneda M. Gastrointestinal stromal tumors in Japanese patients with neurofibromatosis type I. *J Gastroenterol*. 2015 Oct 29. [Epub ahead of print]
 320. Olivier T, Pop D, Chouiter DA, Falk AT, Iannessi A, Saada E, Nettekoven W, Blay JY, Baque P, Cupissol D, Thyss A, Thariat J: Treating metastatic sarcomas locally: a paradoxe, a rationale, an evidence? *Crit Rev Oncol Hematol* 95:62-77, 2015
 321. Omuro A, Chinot O, Taillandier L, Ghesquieres H, Soussain C, Delwail V, Lamy T, Gressin R, Choquet S, Soubeyran P, Huchet A, Benouaich-Amiel A, Lebouvier-Sadot S, Gyan E, Toutilou V, Barrie M, del Rio MS, Gonzalez-Aguilar A, Houillier C, Delgadillo D, Lacomblez L, Tanguy ML, Hoang-Xuan K: Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial. *Lancet Haematol* 2:e251-e259, 2015
 322. Ovarian Cancer Association Consortium, Breast Cancer Association Consortium, and Consortium of Modifiers of BRCA1 and BRCA2, Hollestelle A, van der Baan FH, Berchuck A, Johnatty SE, Aben KK, Agnarsson BA, Aittomäki K, Alducci E, Andrulis IL, Anton-Culver H, Antonenkova NN, Antoniou AC, Apicella C, Arndt V, Arnold N, Arun BK, Arver B, Ashworth A; Australian Ovarian Cancer Study Group, Baglietto L, Balleine R, Bandera EV, Barrowdale D, Bean YT, Beckmann L, Beckmann MW, Benitez J, Berger A, Berger R, Beuselinck B, Bisogna M, Bjorge L, Blomqvist C, Bogdanova NV, Bojesen A, Bojesen SE, Bolla MK, Bonanni B, Brand JS, Brauch H; Breast Cancer Family Register, Brenner H, Brinton L, Brooks-Wilson A, Bruinsma F, Brunet J, Brüning T, Budzilowska A, Bunker CH, Burwinkel B, Butzow R, Buys SS, Caligo MA, Campbell I, Carter J, Chang-Claude J, Chanock SJ, Claes KB, Collée JM, Cook LS, Couch FJ, Cox A, Cramer D, Cross SS, Cunningham JM, Cybulski C, Czene K, Damiola F,

Dansonka-Mieszkowska A, Darabi H, de la Hoya M, deFazio A, Dennis J, Devilee P, Dicks EM, Diez O, Doherty JA, Domchek SM, Dorfling CM, Dörk T, Silva ID, du Bois A, Dumont M, Dunning AM, Duran M, Easton DF, Eccles D, Edwards RP, Ehrencrona H, Ejlertsen B, Ekici AB, Ellis SD; EMBRACE, Engel C, Eriksson M, Fasching PA, Feliubadalo L, Figueroa J, Flesch-Janys D, Fletcher O, Fontaine A, Fortuzzi S, Fostira F, Fridley BL, Friebel T, Friedman E, Friel G, Frost D, Garber J, García-Closas M, Gayther SA; GEMO Study Collaborators; GENICA Network, Gentry-Maharaj A, Gerdes AM, Giles GG, Glasspool R, Glendon G, Godwin AK, Goodman MT, Gore M, Greene MH, Grip M, Gronwald J, Gschwantler Kaulich D, Guénel P, Guzman SR, Haeberle L, Haiman CA, Hall P, Halverson SL, Hamann U, Hansen TV, Harter P, Hartikainen JM, Healey S; HEBON, Hein A, Heitz F, Henderson BE, Herzog J, T Hildebrandt MA, Høgdall CK, Høgdall E, Hogervorst FB, Hopper JL, Humphreys K, Huzarski T, Imyanitov EN, Isaacs C, Jakubowska A, Janavicius R, Jaworska K, Jensen A, Jensen UB, Johnson N, Jukkola-Vuorinen A, Kabisch M, Karlan BY, Kataja V, Kauff N; KConFab Investigators, Kelemen LE, Kerin MJ, Kiemeny LA, Kjaer SK, Knight JA, Knol-Bout JP, Konstantopoulou I, Kosma VM, Krakstad C, Kristensen V, Kuchenbaecker KB, Kupryjanczyk J, Laitman Y, Lambrechts D, Lambrechts S, Larson MC, Lasa A, Laurent-Puig P, Lazaro C, Le ND, Le Marchand L, Leminen A, Lester J, Levine DA, Li J, Liang D, Lindblom A, Lindor N, Lissowska J, Long J, Lu KH, Lubinski J, Lundvall L, Lurie G, Mai PL, Mannermaa A, Margolin S, Mariette F, Marme F, Martens JW, Massuger LF, Maugard C, Mazoyer S, McGuffog L, McGuire V, McLean C, McNeish I, Meindl A, Menegaux F, Menéndez P, Menkiszak J, Menon U, Mensenkamp AR, Miller N, Milne RL, Modugno F, Montagna M, Moysich KB, Müller H, Mulligan AM, Muranen TA, Narod SA, Nathanson KL, Ness RB, Neuhausen SL, Nevanlinna H, Neven P, Nielsen FC, Nielsen SF, Nordestgaard BG, Nussbaum RL, Odunsi K, Offit K, Olah E, Olopade OI, Olson JE, Olson SH, Oosterwijk JC, Orlow I, Orr N, Orsulic S, Osorio A, Ottini L, Paul J, Pearce CL, Pedersen IS, Peissel B, Pejovic T, Pelttari LM, Perkins J, Permut-Wey J, Peterlongo P, Peto J, Phelan CM, Phillips KA, Piedmonte M, Pike MC, Platte R, Plisiecka-Halasa J, Poole EM, Poppe B, Pylkäs K, Radice P, Ramus SJ, Rebbeck TR, Reed MW, Rennert G, Risch HA, Robson M, Rodriguez GC, Romero A, Rossing MA, Rothstein JH, Rudolph A, Runnebaum I, Salani R, Salvesen HB, Sawyer EJ, Schildkraut JM, Schmidt MK, Schmutzler RK, Schneeweiss A, Schoemaker MJ, Schrauder MG, Schumacher F, Schwaab I, Scuvera G, Sellers TA, Severi G, Seynaeve CM, Shah M, Shrubsole M, Siddiqui N, Sieh W, Simard J, Singer CF, Sinilnikova OM, Smeets D, Sohn C, Soller M, Song H, Soucy P, Southey MC, Stegmaier C, Stoppa-Lyonnet D, Sucheston L; SWE-BRCA, Swerdlow A, Tangen IL, Tea MK, Teixeira MR, Terry KL, Terry MB, Thomassen M, Thompson PJ, Tihomirova L, Tischkowitz M, Toland AE, Tollenaar RA, Tomlinson I, Torres D, Truong T, Tsimiklis H, Tung N, Tworoger SS, Tyrer JP, Vachon CM, Van 't Veer LJ, van Altena AM, Van Asperen CJ, van den Berg D, van den Ouweland AM, van Doorn HC, Van Nieuwenhuysen E, van Rensburg EJ, Vergote I, Verhoef S, Vierkant RA, Vijai J, Vitonis AF, von Wachenfeldt A, Walsh C, Wang Q, Wang-Gohrke S, Wappenschmidt B, Weischer M, Weitzel JN, Weltens C, Wentzensen N,

- Whittemore AS, Wilkens LR, Winqvist R, Wu AH, Wu X, Yang HP, Zaffaroni D, Pilar Zamora M, Zheng W, Ziogas A, Chenevix-Trench G, Pharoah PD, Rookus MA, Hooning MJ, Goode EL. No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. *Gynecol Oncol*, (sous presse).
323. Ozmadenci D, Feraud O, Markossian S, Kress E, Ducarouge B, Gibert B, Ge J, Durand I, Gadot N, Plateroti M, Bennaceur-Griscelli A, Scoazec JY, Gil J, Deng H, Bernet A, Mehlen P, Laval F: Netrin-1 regulates somatic cell reprogramming and pluripotency maintenance. *Nat Commun* 6:7398, 2015
324. Pan H, Gazarian A, Buff S, Solla F, Gagnieu MC, Leveneur O, Watrelot-Virieux D, Morisset S, Sobh M, Michallet MC, Roger T, Dubernard JM, Michallet M. (2015) Oral cyclosporine A in neonatal swines for transplantation studies. *Immunopharmacology and Immunotoxicology*. 37(1):19-25.
325. Parker C, Gillessen S, Heidenreich A, Horwich A; ESMO Guidelines Committee. Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2015 Sep;26 Suppl 5:v69-77
326. Patrier-Sallebert S, Bougeard G, Baert-Desurmont S, Lamy A, Flaman JM, Mansuy L, Bronner M, Lasset C, Brugieres L, Golfier F, Frebourg T: Transmission of germline TP53 mutations from male carriers to female partners. *J Med Genet* 52:145-146, 2015
327. Patrikidou A, Domont J, Chabaud S, Ray-Coquard I, Coindre JM, Bui-Nguyen B, Adenis A, Rios M, Bertucci F, Duffaud F, Chevreau C, Cupissol D, Pérol D, Emile JF, Blay JY, Le Cesne A; French Sarcoma Group. Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group. *Eur J Cancer*. 2016 Jan;52:173-80
328. Patry M, Teinturier R, Goehrig D, Zetu C, Ripoche D, Kim IS, Bertolino P, Hennino A: betaig-h3 Represses T-Cell Activation in Type 1 Diabetes. *Diabetes* 64:4212-4219, 2015
329. Penel-Page M, Normand C, Bertrand A, Levard A, Boyle H, Riberon C, Marec-Berard P: [Management of febrile neutropenias in adolescents and young adults: Differences of practice between adult and pediatric units]. *Bull Cancer* 102:915-922, 2015
330. Penel-Page M, Ray-Coquard I, Larcade J, Girodet M, Bouclier L, Rogasik M, Corradini N, Entz-Werle N, Brugieres L, Domont J, Lervat C, Piperno-Neumann S, Pacquement H, Bay JO, Gentet JC, Thyss A, Chaigneau L, Narciso B, Cornille H, Blay JY, Marec-Berard P: Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC'S (Observatoire de l'Utilisation des Therapies Ciblees dans les Sarcomes). *BMC Cancer* 15:854, 2015

331. Pentheroudakis G, Cardoso F, Arnold D, Sessa C, Peters S, Horwich A, Pavlidis N, Stahel R, Cervantes A; ESMO Guidelines Committee. The ESMO guideline strategy: an identity statement and reflections on improvement. *Ann Oncol*. 2015 Sep;26 Suppl 5:v1-7
332. Pereda CM, Lesueur F, Pertesi M, Robinot N, Lence-Anta JJ, Turcios S, Velasco M, Chappe M, Infante I, Bustillo M, Garcia A, Clero E, Xhaard C, Ren Y, Maillard S, Damiola F, Rubino C, Salazar S, Rodriguez R, Ortiz RM, De VF: Common variants at the 9q22.33, 14q13.3 and ATM loci, and risk of differentiated thyroid cancer in the Cuban population. *BMC Genet* 16:22, 2015
333. Perez AF, Devic C, Colin C, Foray N. The low doses of radiation: Towards a new reading of the risk assessment]. *Bull Cancer*. 2015 Jun;102(6):527-38
334. Peron J, Bylicki O, Laude C, Martel-Lafay I, Carrie C, Racadot S: Nonoperative management of squamous-cell carcinoma of the rectum. *Dis Colon Rectum* 58:60-64, 2015
335. Perrier L, Heinz D, Baffert S, Zou Z, Durand Z, I, Rouleau E, Wang Q, Haddad V, Bringuier P, Merlio J, Caumont C, Lacroix L, Marino P, Borget I: Cost Of Genome Analysis: The Sanger Sequencing Method. *Value Health* 18:A353, 2015
336. Perrier L, Nechba A, Perol O, Perol M, Fayette J, Rebattu P, Bonnand S, Philip T, Charbotel B, Fervers B: Cost of Questionnaire-Based Process to Identify Occupational Exposures Among Patients with Lung Cancer. *Value Health* 18:A485, 2015
337. Pertesi M, Galia P, Nazaret N, Vallee M, Garderet L, Leleu X, Avet-Loiseau H, Foll M, Byrnes G, Lachuer J, McKay JD, Dumontet C. Rare Circulating Cells in Familial Waldenstrom Macroglobulinemia Displaying the MYD88 L265P Mutation Are Enriched by Epstein-Barr Virus Immortalization. *PLoS One*, 2015; 10(9): e0136505.
338. Peterlin P, Renneville A, Ben Abdelali R, Nibourel O, Thomas X, Pautas C, de Botton S, Raffoux E, Cayuela JM, Boissel N, Terre C, Celli-Lebras K, Castaigne S, Preudhomme C, Gardin C, Dombret H. Impact of additional genetic alterations on the outcome of patients with NPM1-mutated cytogenetically normal acute myeloid leukemia. *Haematologica*, 2015; 100(5): e196-199.
339. Peterlongo P, Catucci I, Colombo M, Caleca L, Mucaki E, Bogliolo M, Marin M, Damiola F, Bernard L, Pensotti V, Volorio S, Dall'Olio V, Meindl A, Bartram C, Sutter C, Surowy H, Sornin V, Dondon MG, Eon-Marchais S, Stoppa-Lyonnet D, Andrieu N, Sinilnikova OM, Mitchell G, James PA, Thompson E, Marchetti M, Verzeroli C, Tartari C, Capone GL, Putignano AL, Genuardi M, Medici V, Marchi I, Federico M, Tognazzo S, Matricardi L, Agata S, Dolcetti R, Della PL, Cini G, Gismondi V, Viassolo V, Perfumo C, Mencarelli MA, Baldassarri M,

- Peissel B, Roversi G, Silvestri V, Rizzolo P, Spina F, Vivinet C, Tibiletti MG, Caligo MA, Gambino G, Tommasi S, Pilato B, Tondini C, Corna C, Bonanni B, Barile M, Osorio A, Benitez J, Balestrino L, Ottini L, Manoukian S, Pierotti MA, Renieri A, Varesco L, Couch FJ, Wang X, Devilee P, Hilbers FS, van Asperen CJ, Viel A, Montagna M, Cortesi L, Diez O, Balmana J, Hauke J, Schmutzler RK, Papi L, Pujana MA, Lazaro C, Falanga A, Offit K, Vijai J, Campbell I, Burwinkel B, Kvist A, Ehrencrona H, Mazoyer S, Pizzamiglio S, Verderio P, Surralles J, Rogan PK, Radice P: FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor. *Hum Mol Genet* 24:5345-5355, 2015
340. Peterlongo P, Chang-Claude J, Moysich KB, Rudolph A, Schmutzler RK, Simard J, Soucy P, Eeles RA, Easton DF, Hamann U, Wilkening S, Chen B, Rookus MA, Schmidt MK, van der Baan FH, Spurdle AB, Walker LC, Lose F, Maia AT, Montagna M, Matricardi L, Lubinski J, Jakubowska A, Gomez Garcia EB, Olopade OI, Nussbaum RL, Nathanson KL, Domchek SM, Rebbeck TR, Arun BK, Karlan BY, Orsulic S, Lester J, Chung WK, Miron A, Southey MC, Goldgar DE, Buys SS, Janavicius R, Dorfling CM, van Rensburg EJ, Ding YC, Neuhausen SL, Hansen TV, Gerdes AM, Ejlersen B, Jonson L, Osorio A, Martinez-Bouzas C, Benitez J, Conway EE, Blazer KR, Weitzel JN, Manoukian S, Peissel B, Zaffaroni D, Scuvera G, Barile M, Ficarazzi F, Mariette F, Fortuzzi S, Viel A, Giannini G, Papi L, Martayan A, Tibiletti MG, Radice P, Vratimos A, Fostira F, Garber JE, Donaldson A, Brewer C, Foo C, Evans DG, Frost D, Eccles D, Brady A, Cook J, Tischkowitz M, Adlard J, Barwell J, Walker L, Izatt L, Side LE, Kennedy MJ, Rogers MT, Porteous ME, Morrison PJ, Platte R, Davidson R, Hodgson SV, Ellis S, Cole T, Godwin AK, Claes K, Van MT, Meindl A, Gehrig A, Sutter C, Engel C, Niederacher D, Steinemann D, Plendl H, Kast K, Rhiem K, Ditsch N, Arnold N, Varon-Mateeva R, Wappenschmidt B, Wang-Gohrke S, Bressac-de PB, Buecher B, Delnatte C, Houdayer C, Stoppa-Lyonnet D, Damiola F, Coupier I, Barjhoux L, Venat-Bouvet L, Golmard L, Boutry-Kryza N, Sinilnikova OM, Caron O, Pujol P, Mazoyer S, Belotti M, Piedmonte M, Friedlander ML, Rodriguez GC, Copeland LJ, de la Hoya M, Segura PP, Nevanlinna H, Aittomaki K, van Os TA, Meijers-Heijboer HE, van der Hout AH, Vreeswijk MP, Hoogerbrugge N, Ausems MG, van Doorn HC, Collee JM, Olah E, Diez O, Blanco I, Lazaro C, Brunet J, Feliubadalo L, Cybulski C, Gronwald J, Durda K, Jaworska-Bieniek K, Sukiennicki G, Arason A, Chiquette J, Teixeira MR, Olswold C, Couch FJ, Lindor NM, Wang X, Szabo CI, Offit K, Corines M, Jacobs L, Robson ME, Zhang L, Joseph V, Berger A, Singer CF, Rappaport C, Kaulich DG, Pfeiler G, Tea MK, Phelan CM, Greene MH, Mai PL, Rennert G, Mulligan AM, Glendon G, Tchatchou S, Andrulis IL, Toland AE, Bojesen A, Pedersen IS, Thomassen M, Jensen UB, Laitman Y, Rantala J, von WA, Ehrencrona H, Askmalms MS, Borg A, Kuchenbaecker KB, McGuffog L, Barrowdale D, Healey S, Lee A, Pharoah PD, Chenevix-Trench G, Antoniou AC, Friedman E: Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiol Biomarkers Prev* 24:308-316, 2015

341. Peterson DE, Boers-Doets CB, Bensadoun RJ, Herrstedt J; ESMO Guidelines Committee. Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up. *Ann Oncol*. 2015 Sep;26 Suppl 5:v139-51
342. Petit M-A., Berthillon P., Pradat P., Arnaud C., Bordes I., Virlogeux V., Maynard M., Bailly F., Zoulim F., Chemin I. and Trépo C. (2015). Anti-E1E2 antibodies do predict response to triple therapy in treatment-experienced Hepatitis C Virus-cirrhosis cases. *Clin Res Hepatol Gastroenterol.*, in press.
343. Petrylak DP, Vogelzang NJ, Budnik N, Wiechno PJ, Sternberg CN, Doner K, Bellmunt J, Burke JM, de Olza MO, Choudhury A, Gschwend JE, Kopyltsov E, Flechon A, Van AN, Houede N, Barton D, Fandi A, Jungnelius U, Li S, de WR, Fizazi K: Docetaxel and prednisone with or without lenalidomide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet Oncol* 16:417-425, 2015
344. Philippon M, Karsenty G, Bernuz B, Courbiere B, Brue T, Saias-Magnan J, Perrin J: Successful pregnancies and healthy live births using frozen-thawed sperm retrieved by a new modified Hotchkiss procedure in males with retrograde ejaculation: first case series. *Basic Clin Androl* 25:5, 2015
345. Pierga JY, Petit T, Levy C, Ferrero JM, Campone M, Gligorov J, Lerebours F, Roche H, Bachelot T, Charafe-Jauffret E, Bonnetterre J, Hernandez J, Bidard FC, Viens P: Pathological response and circulating tumor cell count identifies treated HER2+ inflammatory breast cancer patients with excellent prognosis: BEVERLY-2 survival data. *Clin Cancer Res* 21:1298-1304, 2015
346. Pinto M, De RM, Dauvergne D, Dedes G, Freud N, Krimmer J, Letang JM, Ray C, Testa E, Testa M: Technical Note: Experimental carbon ion range verification in inhomogeneous phantoms using prompt gammas. *Med Phys* 42:2342-2346, 2015
347. Pivot X, Aulagner G, Blay JY, Fumoleau P, Kaliski A, Sarkozy F, Limat S. Challenges in the implementation of trastuzumab biosimilars: an expert panel's recommendations. *Anticancer Drugs*. 2015 Nov;26(10):1009-16.
348. Pivot X, Viguiier J, Touboul C, Morère JF, Blay JY, Coscas Y, Lhomel C, Eisinger F. Breast cancer screening controversy: too much or not enough? *Eur J Cancer Prev*. 2015 Jun;24 Suppl:S73-6

349. Plesa A, Elhamri M, Clapisson G, Mattei E, Gazzo S, Hequet O, Tigaud I, Michallet M, Dumontet C, Thomas X. Higher percentage of CD34 + CD38- cells detected by multiparameter flow cytometry from leukapheresis products predicts unsustained complete remission in acute myeloid leukemia. *Leuk Lymphoma*, 2015; 56(3): 622-629.
350. Poglio S, Cahu X, Uzan B, Besnard-Guerin C, Lapillonne H, Leblanc T, Baruchel A, Landman-Parker J, Petit A, Baleyrier F, Amsellem S, Baud V, Ballerini P, Pflumio F. Rapid childhood T-ALL growth in xenograft models correlates with mature phenotype and NF-kappaB pathway activation but not with poor prognosis. *Leukemia*, 2015; 29(4): 977-980.
351. Pommier RM, Gout J, Vincent DF, Alcaraz LB, Chuvin N, Arfi V, Martel S, Kaniewski B, Devailly G, Fourel G, Bernard P, Moyret-Lalle C, Ansieau S, Puisieux A, Valcourt U, Sentis S, Bartholin L: TIF1gamma Suppresses Tumor Progression by Regulating Mitotic Checkpoints and Chromosomal Stability. *Cancer Res* 75:4335-4350, 2015
352. Portal A, Pernot S, Tougeron D, Arbaud C, Bidault AT, de la Fouchardiere C, Hammel P, Lecomte T, Dreanic J, Coriat R, Bachet JB, Dubreuil O, Marthey L, Dahan L, Tchoundjeu B, Locher C, Lepere C, Bonnetain F, Taieb J: Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort. *Br J Cancer* 113:989-995, 2015
353. Pouchieu C, Fassier P, Druesne-Pecollo N, Zelek L, Bachmann P, Touillaud M, Bairati I, Hercberg S, Galan P, Cohen P, Latino-Martel P, Touvier M: Dietary supplement use among cancer survivors of the NutriNet-Sante cohort study. *Br J Nutr* 113:1319-1329, 2015
354. Poulalhon N, Dalle S, Balme B, Thomas L. Fast-growing cutaneous squamous cell carcinoma in a patient treated with vismodegib. *Dermatology*, 2015; 230(2): 101-104.
355. Poulard C, Rambaud J, Lavergne E, Jacquemetton J, Renoir JM, Tredan O, Chabaud S, Treilleux I, Corbo L, Le RM: Role of JMJD6 in Breast Tumourigenesis. *PLoS One* 10:e0126181, 2015
356. Pradat P, Virlogeux V, Maynard M, Leclercq M, Hatu G, Amiri M, Lebosse F, Miaillhes P, Zoulim F, Gagnieu MC, Bailly F. Increased Ribavirin Bioavailability Associated With Telaprevir Use in Hepatitis C Patients Treated With PEGylated - Interferon/Ribavirin/Telaprevir Triple Therapy. *Hepat Mon*, 2015; 15(9): e28879.
357. Prevost V, Delorme C, Grach MC, Chvetzoff G, Hureau M: Therapeutic Education in Improving Cancer Pain Management: A Synthesis of Available Studies. *Am J Hosp Palliat Care* 2015

358. Pritchard-Jones K, Bergeron C, de CB, van den Heuvel-Eibrink MM, Acha T, Godzinski J, Oldenburger F, Boccon-Gibod L, Leuschner I, Vujanic G, Sandstedt B, de KJ, van TH, Graf N: Omission of doxorubicin from the treatment of stage II-III, intermediate-risk Wilms' tumour (SIOP WT 2001): an open-label, non-inferiority, randomised controlled trial. *Lancet* 386:1156-1164, 2015
359. Prudent J, Popgeorgiev N, Bonneau B, Gillet G: Bcl-2 proteins, cell migration and embryonic development: lessons from zebrafish. *Cell Death Dis* 6:e1910, 2015
360. Rampazzo C, Tozzi MG, Dumontet C, Jordheim LP: The druggability of intracellular nucleotide-degrading enzymes. *Cancer Chemother Pharmacol* 2015
361. Ranchon F, Boespflug A, Rioufol C, Schwiertz V, Thomas L, Dalle S. New treatments for cutaneous metastatic melanoma: MAPK pathway-targeted and immune based therapies. *Anticancer Agents Med Chem*, 2015; 15(4): 461-467.
362. Ravandi F, Pigneux A, DeAngelo DJ, Raffoux E, Delaunay J, Thomas X, Kadia T, Kantarjian H, Scheuenpflug J, Zhao C, Guo W, Smith BD. Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies. *Blood Cancer J*, 2015; 5:e375.
363. Ravandi F, Ritchie EK, Sayar H, Lancet JE, Craig MD, Vey N, Strickland SA, Schiller GJ, Jabbour E, Erba HP, Pigneux A, Horst HA, Recher C, Klimek VM, Cortes J, Roboz GJ, Odenike O, Thomas X, Havelange V, Maertens J, Derigs HG, Heuser M, Damon L, Powell BL, Gaidano G, Carella AM, Wei A, Hogge D, Craig AR, Fox JA, Ward R, Smith JA, Acton G, Mehta C, Stuart RK, Kantarjian HM. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study. *Lancet Oncol*, 2015; 16(9): 1025-1036.
364. Ray-Coquard I, Pujade-Lauraine E, Ledermann JA: New clinical research strategies for rare gynecologic malignancies. *Curr Opin Obstet Gynecol* 27:53-57, 2015
365. Ray-Coquard IL, Domont J, Tresch-Bruneel E, Bompas E, Cassier PA, Mir O, Piperno-Neumann S, Italiano A, Chevreau C, Cupissol D, Bertucci F, Bay JO, Collard O, Saada-Bouza E, Isambert N, Delcambre C, Clisant S, Le CA, Blay JY, Penel N: Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial. *J Clin Oncol* 33:2797-2802, 2015
366. Rebbeck TR, Mitra N, Wan F, Sinilnikova OM, Healey S, McGuffog L, Mazoyer S, Chenevix-Trench G, Easton DF, Antoniou AC, Nathanson KL, Laitman Y, Kushnir A, Paluch-Shimon S, Berger R, Zidan J, Friedman E, Ehrencrona H, Stenmark-Askmal M, Einbeigi Z, Loman N, Harbst K, Rantala J, Melin B, Huo D, Olopade OI, Seldon J, Ganz PA, Nussbaum RL, Chan SB, Odunsi K, Gayther

- SA, Domchek SM, Arun BK, Lu KH, Mitchell G, Karlan BY, Walsh C, Lester J, Godwin AK, Pathak H, Ross E, Daly MB, Whittemore AS, John EM, Miron A, Terry MB, Chung WK, Goldgar DE, Buys SS, Janavicius R, Tihomirova L, Tung N, Dorfling CM, van Rensburg EJ, Steele L, Neuhausen SL, Ding YC, Ejlertsen B, Gerdes AM, Hansen T, Cajal T, Osorio A, Benitez J, Godino J, Tejada MI, Duran M, Weitzel JN, Bobolis KA, Sand SR, Fontaine A, Savarese A, Pasini B, Peissel B, Bonanni B, Zaffaroni D, Vignolo-Lutati F, Scuvera G, Giannini G, Bernard L, Genuardi M, Radice P, Dolcetti R, Manoukian S, Pensotti V, Gismondi V, Yannoukakos D, Fostira F, Garber J, Torres D, Rashid MU, Hamann U, Peock S, Frost D, Platte R, Evans DG, Eeles R, Davidson R, Eccles D, Cole T, Cook J, Brewer C, Hodgson S, Morrison PJ, Walker L, Porteous ME, Kennedy MJ, Izatt L, Adlard J, Donaldson A, Ellis S, Sharma P, Schmutzler RK, Wappenschmidt B, Becker A, Rhiem K, Hahnen E, Engel C, Meindl A, Engert S, Ditsch N, Arnold N, Plendl HJ, Mundhenke C, Niederacher D, Fleisch M, Sutter C, Bartram CR, Dikow N, Wang-Gohrke S, Gadzicki D, Steinemann D, Kast K, Beer M, Varon-Mateeva R, Gehrig A, Weber BH, Stoppa-Lyonnet D, Sinilnikova OM, Mazoyer S, Houdayer C, Belotti M, Gauthier-Villars M, Damiola F, Boutry-Kryza N, Lasset C, Sobol H, Peyrat JP, Muller D, Fricker JP, Collonge-Rame MA, Mortemousque I, Nogues C, Rouleau E, Isaacs C, De PA, Poppe B, Claes K, De LK, Piedmonte M, Rodriguez G, Wakely K, Boggess J, Blank SV, Basil J, Azodi M, Phillips KA, Caldes T, de la Hoya M, Romero A, Nevanlinna H, Aittomaki K, van der Hout AH, Hogervorst FB, Verhoef S, Collee JM, Seynaeve C, Oosterwijk JC, Gille JJ, Wijnen JT, Gomez Garcia EB, Kets CM, Ausems MG, Aalfs CM, Devilee P, Mensenkamp AR, Kwong A, Olah E, Papp J, Diez O, Lazaro C, Darder E, Blanco I, Salinas M, Jakubowska A, Lubinski J, Gronwald J, Jaworska-Bieniek K, Durda K, Sukiennicki G, Huzarski T, Byrski T, Cybulski C, Toloczko-Grabarek A, Zlowocka-Perlowska E, Menkiszak J, Arason A, Barkardottir RB, Simard J, Laframboise R, Montagna M, Agata S, Alducci E, Peixoto A, Teixeira MR, Spurdle AB, Lee MH, Park SK, Kim SW, Friebel TM, Couch FJ, Lindor NM, Pankratz VS, Guidugli L, Wang X, Tischkowitz M, Foretova L, Vijai J, Offit K, Robson M, Rau-Murthy R, Kauff N, Fink-Retter A, Singer CF, Rappaport C, Gschwantler-Kaulich D, Pfeiler G, Tea MK, Berger A, Greene MH, Mai PL, Imyanitov EN, Toland AE, Senter L, Bojesen A, Pedersen IS, Skytte AB, Sunde L, Thomassen M, Moeller ST, Kruse TA, Jensen UB, Caligo MA, Aretini P, Teo SH: Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. *JAMA* 313:1347-1361, 2015
367. Reddy KR, Zeuzem S, Zoulim F, Weiland O, Horban A, Stanciu C, Villamil FG, Andreone P, George J, Dammers E, Fu M, Kurland D, Lenz O, Ouwerkerk-Mahadevan S, Verbinnen T, Scott J, Jessner W. Simeprevir versus telaprevir with peginterferon and ribavirin in previous null or partial responders with chronic hepatitis C virus genotype 1 infection (ATTAIN): a randomised, double-blind, non-inferiority phase 3 trial. *Lancet Infect Dis.* 2015 Jan;15(1):27-35.
368. Renard C, Ranchere-Vince D: [Ewing/PNET sarcoma family of tumors: towards a new paradigm?]. *Ann Pathol* 35:86-97, 2015

369. Rhondali W, Freyer G, Adam V, Filbet M, Derzelle M, Abgrall-Barbry G, Bourcelot S, Machavoine JL, Chomat-Neyraud M, Gisserot O, Largillier R, Le RA, Priou F, Saltel P, Falandry C: Agreement for depression diagnosis between DSM-IV-TR criteria, three validated scales, oncologist assessment, and psychiatric clinical interview in elderly patients with advanced ovarian cancer. *Clin Interv Aging* 10:1155-1162, 2015
370. Richioud B, Beji H, Pechard M, Sindou M, Chvetzoff G: A Spinal Cord Radiofrequency Destruction. *J Vasc Interv Radiol* 26:1154-1155, 2015
371. Richioud B, Louazon T, Beji H, Bertrand A, Roux P, Kalenderian AC, Cuiet M, Pilleul F, Marec-Berard P: De novo radiologic placement of button gastrostomy: a feasibility study in children with cancer. *Pediatr Radiol* 45:1957-1963, 2015
372. Rios R, Lupianez CB, Campa D, Martino A, Martinez-Lopez J, Martinez-Bueno M, Varkonyi J, Garcia-Sanz R, Jamroziak K, Dumontet C, Cayuela AJ, Wetek M, Landi S, Rossi AM, Lesueur F, Reis RM, Moreno V, Marques H, Jurczynszyn A, Andersen V, Vogel U, Buda G, Orciuolo E, Jacobsen SE, Petrini M, Vangsted AJ, Gemignani F, Canzian F, Jurado M, Sainz J. Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMEnSE consortium. *Endocr Relat Cancer*, 2015; 22(4): 545-559.
373. Robak T, Matutes E, Catovsky D, Zinzani PL, Buske C; ESMO Guidelines Committee. Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2015 Sep;26 Suppl 5:v100-7.
374. Rocas D, Castillo C, Lamarca S, Gallateau-Salle F, Paindavoine S, Pissaloux D, De La Fouchardiere A: Unpigmented nodule with loss of BAP1 expression in a medium-sized congenital nevus. *Eur J Dermatol* 25:201-202, 2015
375. Roche M, Wierinckx A, Croze S, Rey C, Legras-Lachuer C, Morel AP, Fusco A, Raverot G, Trouillas J, Lachuer J: Deregulation of miR-183 and KIAA0101 in Aggressive and Malignant Pituitary Tumors. *Front Med (Lausanne)* 2:54, 2015
376. Roubaud G, Brouste V, Beuzeboc P, Flechon A, Tosi D, Lavau-Denes S, Chevreau C, Culine S, Oudard S, Quivy A, Pourquier P, Houede N: Early objective response may not be a prognostic factor of survival for patients with metastatic urothelial carcinoma: from a retrospective analysis of a cohort of 113 patients. *J Negat Results Biomed* 14:18, 2015
377. Rousset JC, Reynaud Q, Perceval M, Nove-Josserand R, Durupt S, Lega JC, Durieu I: Contraceptive practices and cervical screening in women with cystic fibrosis. *Hum Reprod* 30:2547-2551, 2015
378. Rousset-Jablonski C, Giscard dS, Bernier V, Lornage J, Thomas-Teinturier C, Aubier F, Faure-Contier C: [Gonadal function after treatment for a childhood or adolescent cancer]. *Bull Cancer* 102:602-611, 2015

379. Ruiz S, Lopez-Contreras AJ, Gabut M, Marion RM, Gutierrez-Martinez P, Bua S, Ramirez O, Olalde I, Rodrigo-Perez S, Li H, Marques-Bonet T, Serrano M, Blasco MA, Batada NN, Fernandez-Capetillo O. Limiting replication stress during somatic cell reprogramming reduces genomic instability in induced pluripotent stem cells. *Nature Comm.* 2015. 6:8036.
380. Saada-Bouzig E, Burel-Vandenbos F, Ranchere-Vince D, Birtwisle-Peyrottes I, Chetaille B, Bouvier C, Chateau MC, Peoc'h M, Battistella M, Bazin A, Gal J, Michiels JF, Coindre JM, Pedoutour F, Bianchini L: Prognostic value of HMGA2, CDK4, and JUN amplification in well-differentiated and dedifferentiated liposarcomas. *Mod Pathol* 28:1404-1414, 2015
381. Saison J, Costedoat-Chalumeau N, Maucort-Boulch D, Iwaz J, Marignier R, Cacoub P, Vital-Durand D, Hot A, Tebib J, Aumaitre O, Schleinitz N, Sarrot-Reynaud F, Broussolle C, Seve P. Systemic lupus erythematosus-associated acute transverse myelitis: manifestations, treatments, outcomes, and prognostic factors in 20 patients. *Lupus*, 2015; 24(1): 74-81.
382. Salas S, Brulard C, Terrier P, Ranchere-Vince D, Neuville A, Guillou L, Lae M, Leroux A, Verola O, Jean-Emmanuel K, Bonvalot S, Blay JY, Le CA, Aurias A, Coindre JM, Chibon F: Gene Expression Profiling of Desmoid Tumors by cDNA Microarrays and Correlation with Progression-Free Survival. *Clin Cancer Res* 21:4194-4200, 2015
383. Sanfilippo R, Dileo P, Blay JY, Constantinidou A, Le CA, Benson C, Vizzini L, Contu M, Baldi GG, Dei Tos AP, Casali PG: Trabectedin in advanced synovial sarcomas: a multicenter retrospective study from four European institutions and the Italian Rare Cancer Network. *Anticancer Drugs* 26:678-681, 2015
384. Sargos P, Guerif S, Latorzeff I, Hennequin C, Pommier P, Lagrange JL, Crehange G, Chapet O, de CR, Azria D, Supiot S, Habibian M, Soulie M, Richaud P: Definition of lymph node areas for radiotherapy of prostate cancer: A critical literature review by the French Genito-Urinary Group and the French Association of Urology (GETUG-AFU). *Cancer Treat Rev* 41:814-820, 2015
385. Sarkissian L, Thomas L, Dalle S. Longitudinal melanonychia. *Ann Dermatol Venereol*, 2015; 142(10): 607-608.
386. Sassier M, Dugue AE, Clarisse B, Lesueur P, Avrillon V, Bizieux-Thaminy A, Auliac JB, Kaluzinski L, Tillon J, Robinet G, Le CH, Monnet I, Madroszyk A, Boza G, Falchero L, Fournel P, Egenod T, Toffart AC, Leiber N, Do P, Gervais R: Renal insufficiency is the leading cause of double maintenance (bevacizumab and pemetrexed) discontinuation for toxicity to advanced non-small cell lung cancer in real world setting. *Lung Cancer* 89:161-166, 2015
387. Saunier J, Debarbieux S, Jullien D, Garnier L, Dalle S, Thomas L. Acrodermatitis continua of Hallopeau treated successfully with ustekinumab and acitretin after

- failure of tumour necrosis factor blockade and anakinra. *Dermatology*, 2015; 230(2): 97-100.
388. Sebti J, Desseigne F, Saltel P: Prodromal depression in pancreatic cancer: retrospective evaluation on ten patients. *Palliat Support Care* 13:801-807, 2015
 389. Selmi A, de Saint-Jean M, Jallas AC, Garin E, Hogarty MD, Benard J, Puisieux A, Marabelle A, Valsesia-Wittmann S: TWIST1 is a direct transcriptional target of MYCN and MYC in neuroblastoma. *Cancer Lett* 357:412-418, 2015
 390. Semeraro M, Rusakiewicz S, Minard-Colin V, Delahaye NF, Enot D, Vely F, Marabelle A, Papoular B, Piperoglou C, Ponzoni M, Perri P, Tchirkov A, Matta J, Lapierre V, Shekarian T, Valsesia-Wittmann S, Commo F, Prada N, Poirier-Colame V, Bressac B, Cotteret S, Brugieres L, Farace F, Chaput N, Kroemer G, Valteau-Couanet D, Zitvogel L: Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients. *Sci Transl Med* 7:283ra55, 2015
 391. Senechal C, Rousset-Jablonski C: [Should a systematic fertility preservation be proposed to healthy women carrying a BRCA1/2 mutation?]. *Gynecol Obstet Fertil* 43:800-805, 2015
 392. Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E, Zackrisson S, Cardoso F; ESMO Guidelines Committee. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2015 Sep;26 Suppl 5:v8-30
 393. Seve P, Kodjikian L, Adelaide L, Jamilloux Y. Uveitis in adults: What do rheumatologists need to know? *Joint Bone Spine*, 2015; 82(5): 308-314.
 394. Shekarian T, Valsesia-Wittmann S, Caux C, Marabelle A: Paradigm shift in oncology: targeting the immune system rather than cancer cells. *Mutagenesis* 30:205-211, 2015
 395. Sibaud V, Vigarios E, Combemale P, Lamant L, Lacouture ME, Lacaze JL, Dalenc F, Delord JP: T-DM1-related telangiectasias: a potential role in secondary bleeding events. *Ann Oncol* 26:436-437, 2015
 396. Silva ML, Perrier L, Cohen JM, Paget WJ, Mosnier A, Spath HM: A literature review to identify factors that determine policies for influenza vaccination. *Health Policy* 119:697-708, 2015
 397. Smol T, Nibourel O, Marceau-Renaut A, Celli-Lebras K, Berthon C, Quesnel B, Boissel N, Terre C, Thomas X, Castaigne S, Dombret H, Preudhomme C, Renneville A. Quantification of EVI1 transcript levels in acute myeloid leukemia by RT-qPCR analysis: A study by the ALFA Group. *Leuk Res*, 2015; 39(12): 1443-1447.

398. Sorin T, Fyad JP, Delay E, Rouanet P, Rimareix F, Houpeau JL, Classe JM, Garrido I, Tunon de LC, Dauplat J, Bendavid C, Houvenaeghel G, Clough KB, Sarfati I, Leymarie N, Trudel M, Salleron J, Guillemin F, Oldrini G, Brix M, Dolivet G, Simon E, Verhaeghe JL, Marchal F: Occult cancer in specimens of reduction mammoplasty aimed at symmetrization. A multicentric study of 2718 patients. *Breast* 24:272-277, 2015
399. Sousa B, Furlanetto J, Hutka M, Gouveia P, Wuerstlein R, Mariz JM, Pinto D, Cardoso F; ESMO Guidelines Committee. Central venous access in oncology: ESMO Clinical Practice Guidelines. *Ann Oncol.* 2015 Sep;26 Suppl 5:v152-68.
400. Stacchiotti S, Sommer J; Chordoma Global Consensus Group. Building a global consensus approach to chordoma: a position paper from the medical and patient community. *Lancet Oncol.* 2015 Feb;16(2):e71-83
401. Szulkin R, Karlsson R, Whittington T, Aly M, Gronberg H, Eeles RA, Easton DF, Kote-Jarai Z, Al Olama AA, Benlloch S, Muir K, Giles GG, Southey MC, FitzGerald LM, Henderson BE, Schumacher FR, Haiman CA, Sipeky C, Tammela TL, Nordestgaard BG, Key TJ, Travis RC, Neal DE, Donovan JL, Hamdy FC, Pharoah PD, Pashayan N, Khaw KT, Stanford JL, Thibodeau SN, McDonnell SK, Schaid DJ, Maier C, Vogel W, Luedeke M, Herkommer K, Kibel AS, Cybulski C, Lubinski J, Kluzniak W, Cannon-Albright L, Brenner H, Herrmann V, Holleczeck B, Park JY, Sellers TA, Lim HY, Slavov C, Kaneva RP, Mitev VI, Spurdle A, Teixeira MR, Paulo P, Maia S, Pandha H, Michael A, Kierzek A, Batra J, Clements JA, Albanes D, Andriole GL, Berndt SI, Chanock S, Gapstur SM, Giovannucci EL, Hunter DJ, Kraft P, Le ML, Ma J, Mondul AM, Penney KL, Stampfer MJ, Stevens VL, Weinstein SJ, Trichopoulou A, Bueno-de-Mesquita BH, Tjonneland A, Cox DG, Maehle L, Schleutker J, Lindstrom S, Wiklund F: Genome-wide association study of prostate cancer-specific survival. *Cancer Epidemiol Biomarkers Prev* 24:1796-1800, 2015
402. Tabareau-Delalande F, Collin C, Gomez-Brouchet A, Bouvier C, Decouvelaere AV, de MA, Pages JC, de PG: Chromosome 12 long arm rearrangement covering MDM2 and RASAL1 is associated with aggressive craniofacial juvenile ossifying fibroma and extracranial psammomatoid fibro-osseous lesions. *Mod Pathol* 28:48-56, 2015
403. Tabareau-Delalande F, Collin C, Larousserie F, Bouvier C, Gomez-Brouchet A, Aubert S, Guinebretiere JM, Decouvelaere AV, de MA, Pages JC, de PG: Comments on Carter et al's "activating GNAS mutations in parosteal osteosarcoma". *Am J Surg Pathol* 39:1010-1013, 2015
404. Taillibert S, Conforti R, Bonnetterre J, Bachelot T, Le RE, Bernard-Marty C: [Systemic treatment of brain metastases from breast cancer]. *Cancer Radiother* 19:36-42, 2015

405. Talvas J, Garrait G, Goncalves-Mendes N, Rouanet J, Vergnaud-Gauduchon J, Kwiatkowski F, Bachmann P, Bouteloup C, Bienvenu J, Vasson MP: Immunonutrition stimulates immune functions and antioxidant defense capacities of leukocytes in radiochemotherapy-treated head & neck and esophageal cancer patients: A double-blind randomized clinical trial. *Clin Nutr* 34:810-817, 2015
406. Tawana K, Wang J, Renneville A, Bodor C, Hills R, Loveday C, Savic A, Van Delft FW, Treleaven J, Georgiades P, Uglow E, Asou N, Uike N, Debeljak M, Jazbec J, Ancliff P, Gale R, Thomas X, Mialou V, Dohner K, Bullinger L, Mueller B, Pabst T, Stelljes M, Schlegelberger B, Wozniak E, Iqbal S, Okosun J, Araf S, Frank AK, Lauridsen FB, Porse B, Nerlov C, Owen C, Dokal I, Gribben J, Smith M, Preudhomme C, Chelala C, Cavenagh J, Fitzgibbon J. Disease evolution and outcomes in familial AML with germline CEBPA mutations. *Blood*, 2015; 126(10): 1214-1223.
407. Télouk P, Puisieux A, Fujii T, Balter V, Bondanese VP, Morel AP, Clapisson G, Lamboux A, Albarede F. Copper isotope effect in serum of cancer patients. A pilot study. *Metallomics*. 2015 Feb;7(2):299-308.
408. Terret C, Albrand G, Rainfray M, Soubeyran P: Impact of comorbidities on the treatment of non-Hodgkin's lymphoma: a systematic review. *Expert Rev Hematol* 8:329-341, 2015
409. Tessereau C, Leone M, Buisson M, Duret L, Sinilnikova OM, Mazoyer S: Occurrence of a non deleterious gene conversion event in the BRCA1 gene. *Genes Chromosomes Cancer* 54:646-652, 2015
410. Theillac C, Thomas L, Dalle S. Lentigo maligna. *Ann Dermatol Venereol*, 2015; 142(11): 714-715.
411. Thomas X. Acute myeloid leukemia in the pregnant patient. *Eur J Haematol*, 2015; 95(2): 124-136.
412. Thomas X. Blinatumomab: a new era of treatment for adult ALL? *Lancet Oncol*, 2015; 16(1): 6-7.
413. Thomas X. Chemotherapy plus ponatinib: a new standard for Ph-positive ALL? *Lancet Oncol*, 2015; 16(15): 1451-1453.
414. Thomas X. Novel approaches to pediatric leukemia treatment. *Expert Rev Anticancer Ther*, 2015; 15(7): 811-828.
415. Thomas X. Understanding leukemic hematopoiesis as a complex adaptive system. *World J Stem Cells*, 2015; 7(9): 1145-1149.
416. Thompson CA, Ghesquieres H, Maurer MJ, Cerhan JR, Link BK: Reply to V. Pitini et al and L.J. Costa. *J Clin Oncol* 33:1625-1626, 2015

417. Thonnon C, Faure C, Chopin N, Beurrier F, Quoc CH, Tredan O, Carrabin N: [Metastatic screening before adjuvant chemotherapy in breast cancer]. *Bull Cancer* 102:411-416, 2015
418. Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, Walewski J, André M, Johnson PW, Pfreundschuh M, Ladetto M; ESMO Guidelines Committee. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol*. 2015 Sep;26 Suppl 5:v116-25.
419. Tissot C, Toffart AC, Villar S, Souquet PJ, Merle P, Moro-Sibilot D, Perol M, Zavadil J, Brambilla C, Olivier M, Couraud S: Circulating free DNA concentration is an independent prognostic biomarker in lung cancer. *Eur Respir J* 46:1773-1780, 2015
420. Toffart AC, Sakhri L, Girard N, Couraud S, Merle P, Fournel P, Perol M, Souquet PJ, Timsit JF, Moro-Sibilot D: [Assessment of a tool for decision making in case of worsening condition of cancer patients]. *Rev Mal Respir* 32:66-72, 2015
421. Traore B, Fondrevelle ME, Conde M, Chassagne-Clement C, Kourouma T, Keita AM, Koulibaly M, Sylla BS: Primary Breast Burkitt's Lymphoma in an HIV-Infected Woman. *Case Rep Med* 2015:792041, 2015
422. Tredan O, Campone M, Jassem J, Vyzula R, Coudert B, Pacilio C, Prausova J, Hardy-Bessard AC, Arance A, Mukhopadhyay P, Aloe A, Roche H: Ixabepilone alone or with cetuximab as first-line treatment for advanced/metastatic triple-negative breast cancer. *Clin Breast Cancer* 15:8-15, 2015
423. Tredan O, Lacroix-Triki M, Guiu S, Mouret-Reynier MA, Barriere J, Bidard FC, Braccini AL, Mir O, Villanueva C, Barthelemy P: Angiogenesis and tumor microenvironment: bevacizumab in the breast cancer model. *Target Oncol* 10:189-198, 2015
424. Tredan O, Menetrier-Caux C, Ray-Coquard I, Garin G, Cropet C, Verronese E, Bachelot T, Rebattu P, Heudel PE, Cassier P, Chabaud S, Crougts T, Dupont P, Cadore AC, Clapisson G, Delgado A, Bardin-dit-Courageot C, Rigal C, N'Kodia A, Gilles-Afchain L, Morre M, Perol D, Blay JY, Caux C: ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients. *Ann Oncol* 26:1353-1362, 2015
425. Treilleux I, Arnedos M, Cropet C, Wang Q, Ferrero JM, Abadie-Lacourtoisie S, Levy C, Legouffe E, Lortholary A, Pujade-Lauraine E, Bourcier AV, Eymard JC, Spaeth D, Bachelot T: Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer. *Ann Oncol* 26:120-125, 2015

426. Trinchet JC, Bourcier V, Chaffaut C, Ait Ahmed M, Allam S, Marcellin P, Guyader D, Pol S, Larrey D, De Lédighen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Goria O, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Buffet C, Bacq Y, Wartelle C, Dao T, Benhamou Y, Pilette C, Silvain C, Christidis C, Capron D, Thieffin G, Hillaire S, Di Martino V, Nahon P, Chevret S; and the ANRS CO12 CirVir Group. Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort). *Hepatology*. 2015 Feb 11.
427. Valcourt U, L. B. Alcaraz, J. Y. Exposito, C. Lethias and L. Bartholin. Tenascin-X: beyond the architectural function. *Cell Adhesion and Migration*. 2015; 9(1-2): 154-65.
428. Vallet H, Riviere S, Sanna A, Deroux A, Moulis G, Addimanda O, Salvarani C, Lambert M, Bielefeld P, Seve P, Sibilia J, Pasquali J, Fraison J, Marie I, Perard L, Bouillet L, Cohen F, Sene D, Schoindre Y, Lidove O, Le Hoang P, Hachulla E, Fain O, Mariette X, Papo T, Wechsler B, Bodaghi B, Rigon MR, Cacoub P, Saadoun D. Efficacy of anti-TNF alpha in severe and/or refractory Behcet's disease: Multicenter study of 124 patients. *J Autoimmun*, 2015; 62:67-74.
429. van den Berg H, Paulussen M, Le Teuff G, Judson I, Gelderblom H, Dirksen U, Brennan B, Whelan J, Ladenstein RL, Marec-Berard P, Kruseova J, Hjorth L, Kühne T, Brichard B, Wheatley K, Craft A, Juergens H, Gaspar N, Le Deley MC; Euro-EWING99 Group. Impact of gender on efficacy and acute toxicity of alkylating agent -based chemotherapy in Ewing sarcoma: secondary analysis of the Euro-Ewing99-R1 trial. *Eur J Cancer*. 2015 Nov;51(16):2453-64.
430. van den Heuvel-Eibrink MM, van TH, Bergeron C, Coulomb-L'Hermine A, de CB, Leuschner I, Sandstedt B, Acha T, Godzinski J, Oldenburger F, Gooskens SL, de KJ, Vujanic GM, Pritchard-Jones K, Graf N: Outcome of localised blastemal-type Wilms tumour patients treated according to intensified treatment in the SIOP WT 2001 protocol, a report of the SIOP Renal Tumour Study Group (SIOP-RTSG). *Eur J Cancer* 51:498-506, 2015
431. van Maldegem AM, Benson C, Rutkowski P, Blay JY, van den Berg H, Placzke J, Rasper M, Judson I, Juergens H, Dirksen U, Gelderblom H. Etoposide and carboplatin combination therapy in refractory or relapsed Ewing sarcoma: a large retrospective study. *Pediatr Blood Cancer*. 2015 Jan;62(1):40-4
432. Vanacker H, Bally O, Kassem L, Tredan O, Heudel P, Bachelot T: [Advanced luminal breast cancer (hormone receptor-positive, HER2 negative): New therapeutic options in 2015]. *Bull Cancer* 102:S47-S52, 2015
433. Vannucchi AM, Barbui T, Cervantes F, Harrison C, Kiladjian JJ, Kröger N, Thiele J, Buske C; ESMO Guidelines Committee. Philadelphia chromosome-

- negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol.* 2015 Sep;26 Suppl 5:v85-99
434. Vasseur S, Manie SN: ER stress and hexosamine pathway during tumourigenesis: A pas de deux? *Semin Cancer Biol* 33:34-39, 2015
435. Verbeke S, Richard E, Monceau E, Schmidt X, Rousseau B, Velasco V, Bernard D, Bonnefoi H, MacGrogan G, Iggo RD: Erratum to: Humanization of the mouse mammary gland by replacement of the luminal layer with genetically engineered preneoplastic human cells. *Breast Cancer Res* 17:126, 2015
436. Viaccoz A, Ducray F, Tholance Y, Barcelos GK, Thomas-Maisonneuve L, Ghesquieres H, Meyronet D, Quadrio I, Cartalat-Carel S, Louis-Tisserand G, Jouanneau E, Guyotat J, Honnorat J, Perret-Liaudet A: CSF neopterin level as a diagnostic marker in primary central nervous system lymphoma. *Neuro Oncol* 17:1497-1503, 2015
437. Viguier J, Morère JF, Touboul C, Coscas Y, Blay JY, Lhomel C, Pivot X, Eisinger F. Cancer screening in France: third edition of the EDIFICE survey. *Eur J Cancer Prev.* 2015 Jun;24 Suppl:S68-72.
438. Villiers MB., Cortay JC., Cortès S., Bloquel B., Brichler S., Brakha C., Kay A., Falah N., Zoulim F., Marquette C., Marche PN. and Dény P. (2015). Protein/peptide arrays to detect anti-Delta genotype 1, 6, 8 specific antibodies among Hepatitis D Virus infected patients, by surface plasmon resonance imaging. *J. Clin. Microbiol.*, 53, 1164-71.
439. Vilquin P, Cohen P, Maudelonde T, Tredan O, Treilleux I, Bachelot T, Heudel PE: [New therapeutical strategies in metastatic hormone-dependent breast cancer]. *Bull Cancer* 102:367-380, 2015
440. Vilquin P, Donini CF, Villedieu M, Grisard E, Corbo L, Bachelot T, Vendrell JA, Cohen PA: MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer. *Breast Cancer Res* 17:13, 2015
441. Vizzardì E, Sciatti E, Bonadei I, D'Aloia A, Tartiere-Kesri L, Tartiere JM, Cohen-Solal A, Metra M: Effects of spironolactone on ventricular-arterial coupling in patients with chronic systolic heart failure and mild symptoms. *Clin Res Cardiol* 104:1078-1087, 2015
442. Vlaeminck-Guillem V, Devonec M, Champetier D, Decaussi-Petrucci M, Paparel P, Perrin P, Ruffion A: Urinary PCA3 to predict prostate cancer in a cohort of 1015 patients. *Prog Urol* 25:1160-1168, 2015

443. Vlaeminck-Guillem V, Espiard S, Flamant F, Wemeau JL: TRalpha receptor mutations extend the spectrum of syndromes of reduced sensitivity to thyroid hormone. *Presse Med* 44:1103-1112, 2015
444. Vlaeminck-Guillem V: Prognostic accuracy of prostate health index and urinary prostate cancer antigen 3 in predicting pathologic features after radical prostatectomy. *Urol Oncol* 33:498, 2015
445. Vlaeminck-Guillem V: When Prostate Cancer Circulates in the Bloodstream. *Diagnostics (Basel)* 5:428-474, 2015
446. Wach J, Maucort-Boulch D, Kodjikian L, Iwaz J, Broussolle C, Seve P. Acute anterior uveitis and undiagnosed spondyloarthritis: usefulness of Berlin criteria. *Graefes Arch Clin Exp Ophthalmol*, 2015; 253(1): 115-120.
447. Weingertner N, Neuville A, Chibon F, Ray-Coquard I, Marcellin L, Ghnassia JP: Myxoid liposarcoma with heterologous components: dedifferentiation or metaplasia? A FISH-documented and CGH-documented case report. *Appl Immunohistochem Mol Morphol* 23:230-235, 2015
448. Wiel C, Gras B, Vindrieux D, Warnier M, Gitenay D, Le Calvé B, Ferrand M, Augert A, Bernard D. Multidrug Resistance Protein 3 loss promotes tumor formation by inducing senescence escape. *Oncogene*, 2015
449. William WN Jr, Papadimitrakopoulou V, Lee JJ, Mao L, Cohen EE, Lin HY, Gillenwater AM, Martin JW, Lingen MW, Boyle JO, Shin DM, Vigneswaran N, Shinn N, Heymach JV, Wistuba II, Tang X, Kim ES, Saintigny P, Blair EA, Meiller T, Gutkind JS, Myers J, El-Naggar A, Lippman SM. Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial. *JAMA Oncol*. 2016 Feb 1;2(2):209-16
450. Worthington JJ, Kelly A, Smedley C, Bauche D, Campbell S, Marie JC, Travis MA: Integrin alphavbeta8-Mediated TGF-beta Activation by Effector Regulatory T Cells Is Essential for Suppression of T-Cell-Mediated Inflammation. *Immunity* 42:903-915, 2015
451. Yeh I, Botton T, Talevich E, Shain AH, Sparatta AJ, De La Fouchardiere A, Mully TW, North JP, Garrido MC, Gagnon A, Vemula SS, McCalmont TH, LeBoit PE, Bastian BC: Activating MET kinase rearrangements in melanoma and Spitz tumours. *Nat Commun* 6:7174, 2015
452. Yeh I, De La Fouchardiere A, Pissaloux D, Mully TW, Garrido MC, Vemula SS, Busam KJ, LeBoit PE, McCalmont TH, Bastian BC: Clinical, histopathologic, and genomic features of Spitz tumors with ALK fusions. *Am J Surg Pathol* 39:581-591, 2015
453. You B, Salles G, Bachy E, Casasnovas O, Tilly H, Ribrag V, Sebban C, Henin E, Guitton J, Tod M, Freyer G: Etoposide pharmacokinetics impact the outcomes of

- lymphoma patients treated with BEAM regimen and ASCT: a multicenter study of the LYmphoma Study Association (LYSA). *Cancer Chemother Pharmacol* 76:939-948, 2015
454. Zeisel M.B., Lucifora J., Mason W.S., Sureau C., Beck J., Levrero M., Kann M., Knolle P.A., Benkirane M., Durantel D., Michel M-L., Autran B., Cosset F-L., Strick-Marchand H., Trépo C., Kao J.H., Carrat F., Lacombe K., Schinazi R.F., Barré-Sinoussi F., Delfraissy J-F. and Zoulim F. (2015). Towards an HBV cure: state-of-the-art and unresolved questions-report of the ANRS workshop on HBV cure. Gut, in press.
 455. Zhang H., Diab A., Fan H., Mani S.K., Hullinger R., Merle P. and Andrisani O. (2015). PLK1 and HOTAIR Accelerate Proteasomal Degradation of SUZ12 and ZNF198 during Hepatitis B Virus-Induced Liver Carcinogenesis. *Cancer Res.* 75, 2363-74.
 456. Ziv E, Dean E, Hu D, Martino A, Serie D, Curtin K, Campa D, Aftab B, Bracci P, Buda G, Zhao Y, Caswell-Jin J, Diasio R, Dumontet C, Dudzinski M, Fejerman L, Greenberg A, Huntsman S, Jamroziak K, Jurczyszyn A, Kumar S, Atanackovic D, Glenn M, Cannon-Albright LA, Jones B, Lee A, Marques H, Martin T, Martinez-Lopez J, Rajkumar V, Sainz J, Juul Vangsted A, Watek M, Wolf J, Slager S, Camp NJ, Canzian F, Vachon C. Corrigendum: Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. *Nat Commun*, 2015; 6:10203.
 457. Ziv E, Dean E, Hu D, Martino A, Serie D, Curtin K, Campa D, Aftab B, Bracci P, Buda G, Zhao Y, Caswell-Jin J, Diasio R, Dumontet C, Dudzinski M, Fejerman L, Greenberg A, Huntsman S, Jamroziak K, Jurczyszyn A, Kumar S, Atanackovic D, Glenn M, Cannon-Albright LA, Jones B, Lee A, Marques H, Martin T, Martinez-Lopez J, Rajkumar V, Sainz J, Vangsted AJ, Watek M, Wolf J, Slager S, Camp NJ, Canzian F, Vachon C. Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. *Nat Commun*, 2015; 6:7539.
 458. Zoulim F, Carosi G, Greenbloom S, Mazur W, Nguyen T, Jeffers L, Brunetto M, Yu S, Llamoso C. Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study. *J Hepatol.* 2015 Jan;62(1):56-63
 459. Zoulim F, Durantel D. Antiviral therapies and prospects for a cure of chronic hepatitis B. *Cold Spring Harb Perspect Med.* 2015 Apr 1;5(4). pii: a021501.